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 1 Introduction 
1 Introduction 
 
1.1 Anatomy of the retina 
 
The retina represents the light sensing part of the eye. It lines the back of the eye overlying 
the choroid layer. One characteristic of the vertrebrate inverse retina is the fact that light has 
to pass the nerve cell layer until it reaches the photoreceptor cells. The latter consist of rods 
and cones and represent the light detecting part of the retina. The outer segments of 
photoreceptors are embedded in the light collecting pigment epithelium. In the adjacent outer 
nuclear layer (ONL) the cell bodies of rods and cones are located. Next to the ONL, in the 
outer plexiform layer (OPL) the synapses of rods and cones as well as of bipolar and 
horizontal cells are arranged. They are followed by the inner nuclear layer (INL) which is 
composed of cell bodies of bipolar, horizontal, and amacrine cells. Synaptic connections of 
bipolar cells to ganglion cells are situated in the inner plexiform layer (IPL). The cell bodies of 
the ganglion cells form the ganglion cell layer (GCL). The axons of the ganglion cells 
converge to the optic nerve and transmit the final output of the percepted light to the brain 
(Fig. 1). 
 
 
 
Fig. 1 Schematic representation of the retinal structure. Adapted from 
http://webvision.med.utah.edu/sretina.html. 
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1.2 Anatomy of rods  
 
Rods and cones are the primary light sensitive cells of the retina. In contrast to cones which 
are specialized to the perception of daylight and colours (photopic system), rods are 
responsible for dim light vision (scotopic system). The schematic structure of a rod 
photoreceptor cell is shown in Fig. 2. A rod cell consists of an outer segment, an inner 
segment, the cell body and the synapse. The outer and inner segments are connected with a 
cilium that represents the bottleneck road for the transport of cargo from the cell body to the 
outer segments. Light detection and the downstream signalling transduction take place in the 
outer segments. Their interior space is filled with stacks of membranes called discs. The 
outer membrane encloses the outer segments and is the place of generation of the rod 
membrane potential. 
 
 
 
 
Fig. 2 Schematic view of a rod photoreceptor. Rods are composed of an outer segment that is 
connected to the inner segment via a connecting cilium. The outer segment is filled with discs which 
contain some members of the visual transduction cascade. The inner segment is composed of an 
ellipsoid (containing the mitochondria and the endoplasmic reticulum), the cell body and the synaptic 
terminal. The latter is filled with synaptic vesicles which converge on ribbon synapses and release the 
rod transmitter glutamate.  
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1.3 Signalling transduction in rods 
 
Rods are able to detect even a single photon. This extremely high light sensitivity requires a 
massive signal amplification within the phototransduction cascade.  
In dark, constitutively active gyanylate cyclases (GCs) produce high cGMP levels. High 
cGMP levels in turn keep the cGMP sensitive cyclic nucleotide-gated (CNG) channel in its 
open state and give rise to the influx of Na+ and Ca2+, respectively. This depolarises the rod 
cell up to -40 mV resulting in a “dark current”. Finally, this depolarisation triggers a sustained 
transmitter release at the synapse.  
Photons are absorbed by retinal, a chromophore that is covalently attached to the G protein 
coupled receptor rhodopsin [1]. After absorption, retinal isomerizes from the 11-cis form to 
the all-trans form. This results in conformational changes of rhodopsin (bleaching). One of 
the intermediates of this bleaching process called metarhodopsin II (Rh*) activates the G 
protein transducin which stimulates the cGMP phosphodiesterase (PDE6) to hydrolyse 
cGMP to GMP. The decrease in cGMP concentration in turn leads to the closure of the CNG 
channel. As a consequence, the outer membrane hyperpolarises to -70 mV [2] and gives rise 
to the switch-off of transmitter release to bipolar cells. Thus, the light signal information finally 
sent to the brain is generated by the termination (and not by the generation) of transmitter 
release.  
In order to regenerate the dark current, the rod cell has to restore the cGMP concentration to 
the dark level. This process is regulated by the Ca2+ concentration and by the action of 
gyanylate cyclases (GC-E/F). The latter are controlled by gyanylate cyclase activating 
proteins (GCAPs). In their inactive form, GCAPs bind Ca2+ molecules. During light response, 
the CNG channel is closed and the Ca2+ levels are low [3]. The decrease in Ca2+ levels 
converts GCAP to the active form which then stimulates GCs to produce cGMP. High cGMP 
levels finally lead to opening of CNG channels and to the restoration of the dark current  
(Fig. 3 A).  
Several other mechanisms ensure the inactivation of the signalling cascade and influence 
the photoresponse kinetics. One of them includes the inactivation of Rh* by phosphorylation. 
This step is catalyzed by the rhodopsin kinase [4]. Another protein called arrestin binds to 
phosphorylated rhodopsin and prevents it from activation of transducin [5]. Subsequently, all-
trans retinal is replaced by 11-cis retinal and rhodopsin becomes dephosphorylated. This 
finally gives rise to the recurrence of rhodopsin to its inactive state (Fig. 3 B).  
 
 4 Introduction 
 
Fig. 3 Signalling transduction in rods. A) Molecular mechanisms occurring in the rod outer 
segments upon light induced rhodopsin activation. B) Phosphorylation of Rh* by rhodopsin kinase 
(GRK1) gives rise to binding of arrestin which prevents rhodopsin from sustained activation of 
transducin. For details, see text. NCKX, Na+/Ca2+/K+ exchanger; Gt, transducin; CaM, calmodulin.   
 
1.4 CNG channels 
  
Cyclic nucleotide-gated channels are nonselective cation channels that translate changes in 
the concentration of cAMP or cGMP into an electrical response and/or an intracellular  
Ca2+-signal. Although CNG channels are expressed in different tissues, their function in 
vertebrates has been well characterised only in photoreceptors and olfactory sensory 
neurons so far. Native CNG channels are heterotetramers consisting of A and B subunits 
which together form the central ion conducting pore. The subunit expression and composition 
of CNG channels is tissue dependent. As depicted in Fig. 4, CNG channels from rods are 
composed of three CNGA1 and one CNGB1a subunit [6-8]. In contrast, the cone CNG 
channel comprises two CNGA3 and two CNGB3 subunits [9], and in the olfactory epithelium, 
two CNGA2, one CNGA4 and one CNGB1b form the native CNG channel [10].  
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Fig. 4 Subunit composition of CNG channels. 
 
 
1.4.1 Topology and structural features of CNG channels 
 
CNG channels belong to the superfamily of voltage-gated ion channels. The members of this 
channel group consist of an intracellular N-terminus, six transmembrane domains (S1-S6) 
and an intracellular C-terminus. Transmembrane segments of CNG channels are connected 
to each other by short loops. The last loop located between S5 and S6 forms the pore region. 
The C-terminal domain is subdivided into three functional domains: C-linker, cyclic 
nucleotide-binding domain (CNBD) and the distal C-terminus [11, 12].  
CNG channels are structurally and evolutionary related to hyperpolarisation activated cyclic 
nucleotide-gated (HCN) channels. Recently, the crystal structure of the C-terminus of HCN 
channels consisting of the C-linker and the CNBD was determined (Fig. 5, [13]). The 
comparison of the CNBD of HCN channels to that of other cyclic nucleotide-binding proteins 
like the gene activator protein (CAP, [14]) and cAMP dependent protein kinase (PKG1, [15]) 
reveals that these proteins share very similar folding properties. The C-linker comprises six 
α-helices (A’-F’) followed by an α-helix of the CNBD and a β-roll consisting of eight β-strands 
(1-8). Another short α-helix (called P-helix) is located between β-strands 6 and 7. The last β-
strand is followed by two additional α-helices (B- and C-helix, respectively). 
C-linker and CNBD have been extensively analysed and have been shown to be involved in 
channel gating processes. In contrast, the function of the distal C-terminus has been less 
well-characterised so far. However, this domain has been shown to play an important role in 
channel targeting to the outer membrane of the rod outer segments [16, 17]. 
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Fig. 5 Topology of CNG channels. Left: representative topology of a CNG subunit consisting of the 
intracellular N- and C-terminus and six transmembrane domains (1-6). Right: 3D model of the C-
terminus of CNGB1a based on the molecular dynamics (MD) simulation performed by the group of 
Prof. Dr. Klaus T. Wanner, Department of Chemistry, Ludwig Maximilians Universität München. MD 
simulation was based on the recently identified crystal structure of the C-terminus of HCN2 [13]. For 
details, see text. 
 
1.4.2 Gating of CNG channels  
 
As mentioned above, CNG channels principally can be activated by both cGMP and cAMP. 
However, the ligand affinity, efficacy, open probability, ion permeability or adaptation strongly 
depend on the respective subunit compositions. For example, olfactory CNG channels show 
a similar sensitivity to cAMP and cGMP whereas in rod photoreceptors, the sensitivity of the 
CNG channel to cGMP is much higher compared to cAMP [18, 19]. Electrophysiological 
measurements indicate that gating of CNG channels occurs in a cooperative manner. 
Additionally, it has been shown that the binding of only two ligands is sufficient to fully 
activate the channel. Binding of the remaining two ligands is proposed to have only 
stabilising effects on the open conformation of the channel [20]. Moreover, a preferential 
order of ligand binding to the single subunits also seems to exist, as demonstrated recently 
for olfactory CNG channels [21]. Ligand binding to CNGB1b subunit was proposed to occur 
after the binding of the first two ligands to CNGA4 and CNGA2, respectively. Thus, it was 
concluded that CNGB1b is not involved in the initial opening of the channel but rather in 
stabilising its open state.  
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1.5 Role of CNGB1 in rod CNG channels 
 
1.5.1 Characteristics of the CNGB1 locus 
 
The CNGB1 locus is a complex gene giving rise to the transcription of at least four different 
variants due to alternative splicing. In rod photoreceptors, three transcripts deriving from the 
CNGB1 gene and encoding CNGB1a, GARP1 and GARP2 could be identified [22-24]. In 
olfactory sensory neurons, only CNGB1b is expressed [25]. This splice isoform lacks the 
most part of the long amino terminus which is present in CNGB1a. 
In contrast to CNGA1, CNGB1a subunit is not able to form functional channels when 
expressed alone in heterologous expression systems. However, when coexpressed with 
CNGA1 the CNGB1a subunit confers several characteristic properties to the heteromeric 
channel [24]. For example, heteromeric CNGA1/CNGB1a channels show an increased 
sensitivity to cAMP and are efficiently blocked by L-cis-diltiazem. Furthermore, 
CNGA1/CNGB1a heteromers show a typical single channel flickering behaviour, an 
increased inhibition by calmodulin (CaM), and a decreased block by extracellular Ca2+ [11, 
12, 26, 27].  
The involvement of CNGB1 in the transport of heteromeric channels to their final destination 
represents another important function of this subunit. In the CNGB1 KO model, the transport 
of CNGA2 and CNGA4 to the olfactory cilia as well as the transport of CNGA1 to the outer 
segments is strongly impaired [28, 29]. Recently, some aspects of the molecular 
mechanisms regarding the transport of CNG channels to olfactory cilia and outer segments 
of rod phororeceptors could be clarified. It has been shown that the distal  
C-terminus of CNGB1a plays a crucial role in this process [17, 30].  
 
1.5.2 Retinitis pigmentosa mutations in the CNGB1 gene 
 
Retinitis pigmentosa (RP) is a severe hereditary eye disorder characterised by progressive 
degeneration of photoreceptors and subsequent loss of vision. Degeneration of rod 
photoreceptors is accompanied by loss of dim light vision and by an impairment of contrast 
perception. In later stages of the disease, as a secondary effect, cone photoreceptors often 
also undergo degeneration leading to total blindness. Depending on the affected gene and/or 
the kind of the corresponding mutation, the inheritance of RP may be dominant or recessive. 
In human patients, numerous mutations in different genes have been shown to be causative 
for RP. Many of the RP causing genes encode for members of the signalling transduction 
cascade. Among the rod CNG channel subunits, the vast majority of RP associated 
mutations were identified in the CNGA1 subunit. There are also two reports linking mutations 
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in the CNGB1 locus to recessive form of RP [31, 32]. One of these mutations (c.3444+1G>A) 
represents a splice site mutation positioned on the donor site of Exon 32, the other one 
(c.2978G>T; p.G993V) represents a point mutation located in the CNBD of CNGB1. 
However, so far no functional analysis of these two mutations was performed in order to 
verify their pathogenicity or to decipher the molecular mechanism leading to the RP 
phenotype. 
 
1.6 Role of GARP in rods 
 
The exact molecular functions of the glutamic acid rich proteins, GARP1 and GARP2 (herein 
referred to as GARPs) have not been well characterised so far. GARPs are soluble proteins 
and represent alternatively spliced isoforms of the CNGB1 gene (see chapter 1.5.1). The 
protein sequence of GARPs is almost completely identical to the respective region of the  
N-terminus of CNGB1a. In contrast to GARP1, GARP2 lacks the negatively charged glutamic 
acid rich region and is expressed at high levels in rod outer segments [23, 24, 33].  
Disc rims are regions of the rod disc membranes adjacent to the rod plasma membrane. It 
has been reported that GARP2 interacts with different disc rim associated proteins, like 
peripherin-1 or PDE6 [33-35]. Some of the proposed functions of GARPs arising from these 
studies are the fine-tuning of the cGMP signalling and scaffolding functions, like the 
maintenance of the disc rim integrity and tethering of CNG channels to disc rims. Most 
probably because of their high content of charged glutamic acids, GARPs were also shown 
to have features of natively unfolded proteins [33].  
In contrast to CNGB1 KO mice which do not lack GARPs [28], CNGB1 KO mice deficient for 
both, CNGB1a and GARPs show an impaired structure of outer segments and a spoiled 
discs morphogenesis [36]. However, there are no specific GARP1 or GARP2 KO mice 
available so far.  
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1.7 Goals of this study 
 
This study was set out to address two important  questions: 
1) How do specific mutations in the CNGB1 gene result in RP? 
2) What is the role of CNGB1a in gating of rod CNG channels? 
The main focus of this study was to answer these questions by functional analysis of the two 
RP causing mutations in the CNGB1 gene.  
As described in chapter 1.5.2, the first mutation (c.3444+1G>A) represents a splice site 
mutation positioned on the donor site of Exon 32. This mutation could impact CNGB1a on 
mRNA and on protein level and was therefore tested for splicing and expression in HEK293T 
cells.  
The second mutation (c.2978G>T; p.G993V) is a point mutation located in the CNBD of 
CNGB1a. Since this domain is crucial for proper gating of the CNG channel, the p.G993V 
mutation harbours the potential to impair the gating of these channels. The effects of this 
mutation on channel gating were analysed by different computational, electrophysiological, 
and protein biochemical experiments. 
 
 
 
 
Fig. 6 RP mutations in CNGB1a. Blue box marks the CNBD, green circle shows the position of the 
cGMP binding pocket, and the red arrow the position of the G993V mutation. Since the c.3444+1G>A 
mutation is a splice site mutation located on the donor site of exon 32, its position cannot be marked 
on protein level. Instead, the region in CNGB1a encoded by exon 32 (flanked by two red dashed lines) 
is shown. GARP, glutamic acid rich protein domain. 
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2 Materials and methods 
 
2.1 Molecular biology 
 
2.1.1 Plasmids 
 
pcDNA3.1 vector 
pcDNA3.1 (Invitrogen) represents a commonly used mammalian expression vector. It 
consists of following elements: 
- Cytomegalovirus (CMV) promoter, capable of driving heterologous gene 
expression in mammalian cell lines. 
- Simian virus (SV40) origin of replication (ori), allowing for replication in 
mammalian cells. 
- Colicinogenic factor E1 (ColE1) ori, responsible for replication in prokaryotes. 
- Filamentous phage (f1) ori which allows recovery of single stranded plasmids in 
prokaryotes. 
- Multiple cloning site (MCS) for introduction of genes or gene fragments of interest. 
- Polyadenylation signal (pA) of the bovine growth hormone (BGH). 
- Neomycin resistance (NeoR) under the control of SV40 promotor for selection of 
stable mammalian cell lines.  
- Ampicillin resistance (AmpR) for selection of recombinant bacterial cells. 
 
pCRII®-TOPO® vector 
This vector was used for subcloning of PCR products (see chapter 2.1.8). It contains a lacZ 
promoter followed by the MCS and lacZ reporter gene. Thus, insertion of constructs into the 
MCS disrupts the expression of β-galactosidase and can be used for selection of 
recombinant bacterial clones on X-gal containing plates. Additionally, this vector contains a 
f1 ori and pUC ori for plasmid replication in prokaryotes. For selection of recombinant 
bacteria, kanamycin and ampicillin resistance (AmpR) are included in this vector.  
 
pIRESeGFP vector 
pIRESeGFP vector allows the gene of interest and enhanced green fluorescent protein 
(eGFP) to be expressed simultaneously but separately from a bicistronic mRNA. This is 
assured by the presence of an internal ribosome entry site (IRES) of encephalomyocarditis 
virus (EMCV) located between the MCS and coding region of GFP. Additionally, this vector 
contains following elements: 
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CMV promoter, SV40 pA, SV40 promotor, SV40 ori, f1 ori, KanR, NeoR, pUC ori and the 
herpes simplex virus thymidine kinase (HSV-TK) pA.  
 
2.1.2 Polymerase chain reaction (PCR) 
 
The conditions of each PCR reaction were adjusted to the respective application. Table 1 
shows an overview about the standard PCR conditions of different polymerases used in this 
study: 
 
Table 1 Standard PCR conditions for different polymerases. 
Polymerase Taq Pfu (Stratagene) Herculase 
(Stratagene) 
Phusion 
(Finnzymes) 
Initial denaturation 95°C 1 min 95°C 1 min  95°C 1 min  98°C 30 sec  
Denaturation 95°C 30 sec 95°C 45 sec  95°C 20 sec  98°C 10 sec 
Annealing 
 X °C 30 sec  X °C 45 sec  X °C 20 sec  X °C 30 sec  
Elongation 72°C 30 sec/kb 72°C 1 min/kb 72°C 30 sec/kb 72°C 30  sec/kb 
Final elongation 72°C 5 min 72°C 5 min  72°C 5 min  72°C 5 min  
Storage 10°C ∞ 10°C ∞ 10°C ∞ 10°C ∞ 
 
The pipetting scheme of the PCR was adapted from the manual of the respective 
manufacturer. 
 
2.1.3 Purification of DNA fragments 
 
After PCR amplification, the PCR products may be purified for further applications. The 
purification was performed using the PureLinkTM Quick Gel Extraction Kit (Invitrogen) 
accoriding to manufacturar’s protocol. All solutions needed for this procedure were provided 
with the kit. Briefly, fivefold amount of solubilization buffer was added to the PCR product and 
the solution was loaded on the column. The latter was placed in 2 mL Eppendorf tubes and 
was centrifuged at max. speed for 45 sec at room temperature. The flow through was 
discarded and 700 µL wash buffer was added to the column following by an additional 
centrifugation at identical conditions. After discarding the flow through, the column was spun 
at max. speed for 2 min at room temperature in order to remove all ethanol present in the 
wash buffer. Now, 30 µL ddH2O or elution buffer was added on the center of the column 
which was allowed to incubate 10 min at room temperature. Finally, the DNA was eluted into 
a fresh 1.5 mL Eppendorf tube by centrifugation at max. speed for 45 sec at room 
35 x 
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temperature. To check for proper purification, 5 µL of the purified DNA were loaded on 
agarose gel.  
 
2.1.4 Restriction analysis and preparation of samples for cloning 
 
Restriction enzymes were purchased from New England BioLabs (NEB) or from Fermentas. 
Restriction analysis conditions were performed following the manufacturer’s instructions.  
For cloning applications, the amount of DNA in the restriction reaction was 3-5 µg. After the 
incubation time, the cut DNA was loaded on the appropriate agarose gel and was allowed to 
run until sharp bands could be cut off from the gel. Then, the cut piece of gel was weighed 
and the threefold volume of gel solubilization buffer (PureLinkTM Quick Gel Extraction Kit, see 
chapter 2.1.3) was added (i. e. if the gel piece weighed 200 mg, the amount of gel 
solubilization buffer was 600 µL). Now, the sample was incubated at 55°C for 5-10 min or 
until the gel was completely solved. This solution was loaded on the columns from the Quick 
Gel Extraction Kit and the the same procedure as described in chapter 2.1.3 was performed. 
 
2.1.5 Ligation and dephosphorylation 
 
Ligation reaction was performed using following pipetting scheme: 
 
x   µL vector DNA 
y   µL insert DNA 
2   µL T4 ligase buffer (NEB) 
1   µL T4 ligase (NEB) 
20 µL total volume 
 
This reaction was incubated for 30 min - 2 h at room temperature. The vector-to-insert ratio 
was variable and was determined empirically for each ligation considering the amount of the 
respective DNA observed on the check agarose gel after the DNA purification. After the 
ligation vector DNA was dephosphorylated by following protocol: 
3 µL of the Fast AP buffer and 2 µL of Fast AP (Fermentas) were added to the ligation 
reaction which was then incubated at 37°C for 10 mi n. Subsequently, the enzyme was heat 
inactivated by incubating the reaction at 65°C for 15 min.  
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2.1.6 Transformation 
 
For transformation different chemically competent E.coli strains were used depending on the 
application. First, 100 µL aliquots of competent cells (stored at -80°C) were thawed on ice. 
Then, 1-3 µL DNA (i. e. ligation reaction) were added to the cell suspension which was gently 
swirled and was allowed to incubate on ice for 5 min. Now, a heat pulse was applied by 
incubating the cells for 30 sec at 42°C in a water bath. Immediately after this, the cell 
suspension was placed on ice for 2 min. If the resistance for selection of the plasmid DNA 
was ampicillin, the cells were directly plated on the appropriate agar plates. In cases of 
chloramphenicol or kanamycin resistance, 900 µL prewarmed LB(+) medium was added to 
the cells. The latter were incubated for 1 h at 37°C with shaking followed by an centrifugation 
at 3500 rpm for 5 min at room temperature. Approx. 800 µL of the supernatant was removed 
and the cells were resuspended in the remaining part of the LB(+) medium. Finally, the cells 
were plated on the respective agar plates and incubated over night at 37°C.  
 
LB(+) medium   LB(+) Agar 
 
Pepton 10 g   Agar 15 g   
Yeast extract   5 g   LB(+) medium ad 1 L 
NaCl    5 g    autoclave 
Glucose   1 g   for preparing resistant agar plates, cool the LB(+) agar  
ddH2O ad 1 L   medium to 55°C and add the appropri ate resistance in 
adjust pH to 7.2 - 7.5   concentrations described in chapter 0. 
autoclave 
 
2.1.7 Inoculation of bacterial cells and isolation of plasmid DNA (alkaline lysis)  
 
Bacterial clones were picked from the plate and were transferred to 10 mL polypropylene 
tubes containing the LB(+) medium with the appropriate resistance (ampicillin: 100 µg/mL, 
kanamycin: 30 µg/mL, chloramphenicol: 30 µg/mL). Then, the suspension was incubated 
over night at 37°C with shaking (225 rpm). On the n ext day, the cells were spun at 1000 x g 
for 10 min at room temperature or at 4°C and were r esuspended in 250 µL resuspension 
buffer. This solution was transferred into 2 mL Eppendorf tubes. After adding 250 µL lysis 
buffer the cell suspension was inverted several times and was allowed to incubate for max. 5 
min at room temperature. Now, 250 µL neutralization solution was added to the mix, was 
inverted, and was incubated for 5 min at room temperature. Next, the suspension was 
centrifuged at rpm max. for 15 min at 4°C or at roo m temperature. The supernatant 
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containing the plasmid DNA was transferred into fresh 1.5 mL Eppendorf tubes. To 
precipitate DNA, 520 µL 100 % isopropanol was added to the mix. After vortexing, the mix 
was spun at rpm max. for 15 min at 4°C. Subsequentl y, the pellet was washed with 70 % 
ethanol and the solution was centrifuged at rpm max. for 5 min at 4°C. Then, the supernatant 
was discarded and the pellet was dried in a vacuum centrifuge at room temperature for  
5 min. Now, the pellet was suspended in 30 µL of ddH2O and 1 µL of this plasmid DNA 
solution was used for control restriction analysis. If the expected results were obtained from 
this restriction analysis, the corresponding plasmid DNA was send for sequencing without 
further purification.  
To yield plasmid DNA in larger amounts and in higher purity, PureYieldTM Plasmid Midiprep 
System (Promega) was used. For that purpose, colonies were inoculated in 100-200 mL 
LB(+) medium and similar procedure as described above was performed following the 
manufacturer’s instructions.  
 
2.1.8 TOPO cloning 
 
TOPO cloning (TOPO TA Cloning® Kit Dual Promotor, Invitrogen) represents a rapid and 
convenient cloning method for PCR products. Topoisomerase I from Vaccinia virus [37] 
attached to the pCRII®-TOPO® vector allows for covalent bonding of PCR products to this 
vector. However, this reaction only takes place if the respective PCR product posesses a 
deoxyadenosine (A) on it’s 3’ end. In contrast to most polymerases with proof reading activity 
(i.e. Pfu-polymerase), conventional Taq polymerase has terminal transferase activity that 
adds a single “A” to the 3´ ends of the PCR products.  
First, PCR products which were amplified using a polymerase without terminal transferase 
activity were purified by standard procedures as described in chapters 2.1.3 and 2.1.4. Then, 
following components were added to 8 µL of the purified PCR product: 
0.5 µL dNTP (10 mM each) 
1 µL Taq buffer (containing 2.5 mM MgCl2)  
0.5 µL Taq-Polymerase 
This reaction was incubated for 30 min at 72°C and was placed on ice. TOPO cloning 
reaction was performed using following pipetting scheme: 
4.5  µL of the Taq polymerase reaction product 
1 µL salt solution (provided with the kit) 
0.5 µL TOPO vector (provided with the kit) 
The mix was incubated for 20 min at room temperature and 2-3 µL were used for 
transformation of chemically competent bacterial cells as described in chapter 2.1.6.  
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2.1.9 In-Fusion cloning 
 
For some cloning applications, as a alternative to mutagenesis PCR and/or overlap-PCR,  
In-FusionTM Advantage PCR Cloning Kit (Clontech) was used. PCR products sharing a 15 bp 
homology with the sequence at the ends of the linearized vector can be covalently attached 
to the vector giving rise to circular plasmid DNA. The In-Fusion enzyme provided with the kit 
catalyzes this covalent bounding.  
The In-Fusion reaction was set up as follows: 
≈ 100 ng purified PCR product 
≈ 200 ng purified vector 
       2 µL 5 x In-Fusion reaction buffer 
       1 µL In-Fusion enzyme 
Ad 10 µL ddH2O 
If larger volumes of vector or insert were used, the volume of buffer, of the enzyme and the 
total volume were doubled. The In-Fusion mix was now incubated at 37°C for 15 min 
following by an incubation at 50°C for 15 min. Then , the reaction was placed on ice and 
diluted in TE buffer (pH 8.0) up to a volume of 50 µL. Finally, 3-5 µL of this solution were 
used for a standard transformation protocol. 
 
TE Buffer 
 
10 mM Tris-HCl pH 8.0 
  3 mM EDTA   
 
2.1.10 Introduction of mutations in DNA constructs 
 
In most cases, mutations were introduced by means of site directed mutagenes. Site directed 
mutagenesis PCR was performed using the QuickChange XL Site-Directed Mutagenesis Kit 
(Stratagene) according to manufacturer’s instructions or by overlap-PCR. The latter requires 
a two-step PCR reaction. Thereby, the choice of appropriate overlap primers allows for 
deletion or insertion of desired DNA sequences. In the first PCR reaction, two separate PCR 
products were amplified which share a sequence homology (“overlap”) at their 3’ ends. After 
the purification of the PCR products by gel extraction, they were used as DNA template for 
the second PCR reaction. Routinely, in this study overlap PCR was performed using the Pfu 
polymerase.  
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2.1.11 Reverse transcription (RT) 
Reverse transcription was performed using the ThermoScriptTM RT-PCR System Kit 
(Invitrogen) following the instructions of the manufacturer. During the cDNA synthesis, 
random hexamers as well as oligo(dT) primer were added to the reaction. After the cDNA 
synthesis, herculase (Stratagene) was used for the subsequent PCR. 
 
2.1.12 Cloning of CNG channels 
 
Cloning of the rat CNGB1a/CNGB1b and CNGA2/CNGA4 subunits was described previously 
[25, 38, 39]. Bovine CNGA1 was a gift of Dr. U. Benjamin Kaupp (Caesar Bonn). As far as 
not otherwise mentioned, all experiments from the electrophysiological and biochemical 
recordings described in chapter 3.2 were obtained using rat CNGB1 an bovine CNGA1 
channels. Human CNG channels were PCR amplified from retinal cDNA, were subcloned 
into the pcDNA3.1 and/or pIRESeGFP vector and sequenced.   
 
2.2 Cell culture 
 
2.2.1 Cultivation and transfection of mammalian cell lines 
 
For most in vitro transfections in this study, HEK293T cells were used. They were cultivated 
in DMEM + GlutaMAXTM-I medium (+ 4,5 g/L glucose, - pyruvate + 10 % FBS + 1 % 
penicillin/streptomycin) at 37°C with 10 % CO 2. COS7 cells were cultivated under same 
conditions in DMEM + GlutaMAXTM-I medium (+ 4,5 g/L glucose, + pyruvate + 10 % FBS +  
1 % penicillin/streptomycin). 
Transient transfections of HEK293T cells or COS7 cells were performed using the calcium 
phosphate technique [40] or with FuGENE® (Promega). The calcium phosphate based 
transfection was performed by adding following solutions to a 15 mL Falcon tube: 
10   µg DNA,  
50   µL 2,5 M CaCl2 
ad 500 µL ddH2O  
While vortexing this mix, 2 x BBS solution was added drop wise. Then, the mix was 
incubated for max. 5 min at room temperature. This mixture was added drop wise to the  
40-70 % confluent cells which subsequently are incubated at 37°C with 3-5 % CO 2. 8-16 h 
after the transfection, medium was replaced and the cells were incubated at 37°C with  
10 % CO2 until harvesting. The amounts of different components described above 
 17 Materials and methods 
correspond to ∅ 10 cm plates. For ∅ 15 cm plates, the volume of all solutions was doubled 
and the amount of DNA was increased to 25-30 µg.  
Transfection with FuGENE® (Roche) was performed for subsequent immunocytochemical 
and electrophysiological applications. For 16-well plates 30 ng DNA was used per well, for  
∅ 3.5 cm plates 3 µg DNA was used. First, fresh GlutaMAXTM-I medium (without FBS and 
without penicillin/streptomycin) was added to cryo tubes followed by the addition of DNA. 
Thereby, tenfold volume of medium related to the total volume on DNA was added (i. e. 1 µL 
DNA corresponds to 10 µL medium). After the 5 min incubation, FuGENE was added directly 
to the reaction which was mixed subsequently by pipetting up and down. In this case, 
threefold volume of FuGENE in µL was used related to the amount of DNA in µg (i. e. 1 µg 
DNA corresponds to 3 µL FuGENE). This reaction was allowed to incubate for 30 min at 
room temperature and was then added directly to the medium of the cells. The latter were 
incubated at 37°C with 10 % CO2 until proceeding wi th the respective application.  
 
2 x BBS Solution 
 
10,65  g BES 
16,35  g NaCl 
  0,21  g Na2HPO4 · 2H2O 
ad 950 mL H2O 
adjust to pH 6,95 with NaOH 
ad 1L ddH2O 
steril filtrate  
 
2.3 Protein biochemistry 
 
2.3.1 Isolation and quantification of proteins  
 
Proteins were isolated from cultured mammalian cells by the following protocol: 
48 h after transfection, medium was removed and the cells were harvested in a 1.5 mL 
Eppendorf tube. Then, the suspension was centrifuged at 4°C for 5 min at 1000 x g. 
Hereafter, the pellet was resuspended in lysis buffer and was rotated at 4°C for 30 min. 
Subsequently, the cells were spun at 4°C for 10 min  at rpm max. and the supernatant was 
transferred into a fresh 1.5 mL Eppendorf tube.  
For protein isolation from mouse tissue, the latter was suspended in lysis buffer containing 
the proteinase inhibitor cocktail mix (Roche) and the tissue disruption was performed using 
the Potter S homogenizer (B. Braun Biotech International). Then, the suspension was 
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centrifuged at 4°C at rpm max. and the supernatant was transferred into fresh 1.5 mL 
Eppendorf tubes.  
To determine the concentration of isolated proteins, Bradford assay was performed [41]. 
Thereby, 5 µL of the protein solution (5 µL lysis buffer were used as blank control) were 
transferred into 1 mL plastic cuvettes followed by an addition of 95 µL 0.15 M NaCl solution. 
Then, 1 mL coomassie blue solution was added and was allowed to incubate for 2 min at 
room temperature. Immediately after the incubation time, protein concentration was 
measured using the Bradford assay program on the BioPhotometer (Eppendorf).  
 
1 x Lysis Buffer    Coomassie Blue Solution 
 
  2.5 mL Triton X-100    50 mg coomassie brilliant blue G250  
   15 mL 5 M NaCl    25 mL 95 % ethanol 
 400 µL  2.5 M CaCl2    50 mL 85 % phosphoric acid (H3PO4) 
      ad 500 mL ddH2O 
2.3.2 Membrane preparations 
 
For enrichment of membrane proteins, preparations of cell membranes were performed. For 
this purpose, 1-2 mL of the 1 x membrane preparation buffer containing the proteinase 
inhibitor cocktail mix was added to the harvested HEK293T cells or mouse tissue and the 
breakup of cell or of the tissue was performed using the Potter S homogenizer. Then, the 
suspension was centrifuged at 4°C for 10 min at 500 0 x g. The supernatant was transferred 
into 6 mL ultracentrifuge tubes and 1 x membrane preparation buffer was added to a final 
volume of 4 mL. Ultracentrifugation was performed at 4°C for 45 min at 30000 rpm (Beckman 
45 Ti rotor). Pellet was suspended in 50-100 µL 1 x membrane preparation buffer and 5 µL 
were used for determination of the protein concentration as described in chapter 2.3.1.  
 
3 x Membrane Preparation Buffer:   
   
3,15     g  MOPS  
   77     g  Sucrose 
     6     mL  0.5 M EDTA (pH 7.4) 
ad 250 mL   ddH2O                          
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2.3.3 Western blotting 
 
Western blotting was performed by standard procedures. After the protein transfer to the 
PVDF membrane, the latter was shortly equilibrated with methanol and was blocked in  
5 % milk powder for 1 h at room temperature with shaking. Then, the incubation of the 
membrane with the appropriate primary antibody was performed. The optimal incubation time 
and the optimal antibody concentration were determined empirically. Hereafter, the 
membrane was washed three times in TBST for 5 min followed by an 1-2 h incubation with 
the secondary antibody at room temperature with rotation. Now, the membrane was washed 
3-4 times with TBST for 5 min and once in ddH2O. After the incubation with the luminol 
reagent according to manufacturer’s protocol (Millipore or Santa Cruz), the membrane was 
put into a film cassette and was exposed to a x-ray film (Fuji). The optimal exposure time 
was determined empirically. 
  
10 x TBS     1 x TBST  
 
12.1 g Tris    100 mL TBS 
80.2 g NaCl    0.1 % Tween 
ad 1 L ddH2O    protect from light  
 
2.3.4 Co-immunoprecipitation 
 
To analyse protein-protein interactions, co-immunoprecipitation experiments using protein G 
dynabeads (Invitrogen) were performed. First, approx. 5 µg antibody and PBS were added to 
30 µL dynabeads up to a final volume of 500 µL. This solution was rotated for 30 min at 4°C    
and subsequently, the supernatant was removed on the magnet followed by a wash step with 
200 µL PBS. Then, 1 mg of the protein lysate was added to the beads and the reaction was 
filled up with PBS to a final volume of 500 µL. Now, the suspension was rotated for 30 min at 
4°C followed by three washing steps with PBS. After  the last wash, the suspension was 
transferred into fresh 1.5 mL Eppendorf tubes and the supernatant was removed completely. 
Beads were resuspended in 6 x Lämmli buffer (with or without DTT, depending on the 
application) and were incubated at 70°C for 15 min.  Finally, the supernatant was loaded on 
the appropriate SDS PAGE gel.   
In some cases, the antibody and IgG’s of protein G were crosslinked to the beads by means 
of irreversible, non-cleavable crosslinker BS3 (Thermo Scientific). For this purpose, after the 
coupling of the antibody to the beads, BS3 was added to the reaction in a final concentration 
of 5 mM. Then, the suspension was incubated for 30 min at room temperature and was 
 20 Materials and methods 
quenched subsequently by adding Tris-HCl pH 7.5 (final concentration 50 mM) and 
incubating the reaction for 15 min at room temperature. Then, protein lysate was added and 
the reaction was processed as described above. 
 
6 x Lämmli     6 x Lämmli + DTT 
 
7  mL 4 x Tris-HCl/SDS pH 6.8  = 6 x Lämmli 
3  mL glycerol    + 930 mg DTT 
1  g    SDS 
1.2   mg bromphenolblue  
ad 10  mL ddH2O 
 
2.3.5 Biotinylation assay 
 
Biotinylation represents a commonly used method for detection of cell surface proteins [42].  
48 days after transfection, medium was removed from HEK293T cells which then were 
washed with PBS. Cell surface biotinylation was performed using 0.8 mM of non-cell 
permeable sulfo-NHS-SS-biotin (Pierce, Rockford) in PBS for 30 minutes at 4°C. The 
reaction was stopped with 10 mM glycine and the cells were transferred into fresh 50 mL 
Falcon tubes. After 2 wash steps with PBS (each time pelleting the cells by centrifugation at 
4°C for 5 min at 1500 x g), the cell pellet was sol ubilised in 1 x lysis buffer with the proteinase 
inhibitor cocktail mix (see chapter 2.3.1). Then, biotinylated proteins were precipitated on 
Neutravidin agarose resin (Pierce) using 80 µL of neutravidin beads per reaction. First, 
beads were washed with 200 µL PBS and centrifuged after each wash step at 4°C for 1 min 
at 2500 x g. Biotinylated protein lysate (400 µg/reaction) was added to the washed beads 
and was rotated for 2 h at 4°C. Next, the suspensio n was washed 4 additional times with 
PBS containing 1 % NP-40 under the same centrifugation conditions as described above.   
Finally, elution was performed by adding 40 µL of elution buffer to the beads. Samples were 
incubated 10 min at 70°C before loading them on the  SDS PAGE gel.  
 
Elution Buffer  
 
280 µL  PBS 
  40 µL 10 % NP-40  
  80 µL  6 x Lämmli buffer + DTT 
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2.4 Förster resonace energy transfer (FRET)  
 
FRET represents a commonly used tool for the analysis of molecular dynamics such like 
protein-protein interactions [43]. This method is based on the energy transfer between two 
fluorophores located in a defined spatial proximity to each other (Typically, less then 10 nm). 
Thereby, the emission spectrum of the first fluorophore (donor) is partially absorbed by the 
second fluorophore (acceptor) giving rise to a decrease in the emmision spectrum of the 
donor and an increase of the acceptor emission spectrum. This spectral shift is finally 
measured as FRET signal. However, a prerequisite for a FRET signal is a spectral overlap of 
the donor and the acceptor. Based on this, for biological use the most commonly used pair of 
fluorophors is the combination of CFP as donor and YFP as acceptor. Interaction of proteins 
of interest can be studied by coupling them to these fluorophores, by coexpressing them in 
an appropriate cell line and by subsequent measurement of the FRET signal. In this study, 
FRET was used to analyse the assembly of CNGB1a subunits carrying the GV mutation with 
the CNGA1 subunit using following protocol: 
HEK293 cells were transfected with CNGA1-CFP or soluble CFP (negative control) and 
wildtype or mutant YFP-CNGB1a. A CFP-YFP tandem construct served as FRET positive 
control [44]. Fluorescent images were captured 48-72 h after transfection on an Axioplan 2 
microscope (Zeiss, Oberkochen, Germany) equipped with a Plan Neofluar 40 x objective 
(numeric aperture 0.75), a HMRc ccd camera and an AttoArc HBO100 mercury lamp 
illumination unit. Three fluorescent images per cell were collected using the CFP HC filter, 
YFP HC filter and FRET CFP-YFP HC filter sets (Semrock, Rochester). Fluorescence 
images were processed using the FRET plus macro (Zeiss) and the FRET efficiency was 
calculated as N-FRET using the method described by Xia and Liu [45]. 
 
2.5 Electrophysiological recordings 
 
All experiments obtained from electrophysiological recordings in this study were performed 
by PD Dr. Xiangang Zong as described previously [25, 46, 47]. Maximal channel open 
probability (Pmax) was determined from the ratio of currents at saturating cGMP (1 mM) in the 
absence and the presence of 1 µM Ni2+ as described previously [48, 49]. The following 
adjustments to the solutions were made for these experiments: KCl or NaCl with less than 
0.01 ppm Ni2+ was used and HEPES concentration was lowered to 5 mM. EGTA / EDTA 
were omitted from the extracellular solution. The pipette solution contained 200 mM EDTA 
and 500 mM niflumic acid. 
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2.6 Statistics  
 
All values are given as mean ± S.E., and n is the number of experiments. An unpaired 
Student's t test was performed for the comparison between two groups. Values of p < 0.05 
were considered significant. 
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3 Results 
 
3.1 Splicing analysis of the c.3444+1G>A mutation in CNGB1 
 
As described in chapter 1.5.2 the c.3444+1G>A splice site mutation in CNGB1 has been 
associated with RP [32]. This mutation is located at the donor site of exon 32 and has been 
proposed to result in a frameshift and truncation of the last 28 amino acids (aa) of the 
corresponding protein. However, this ambiguous conclusion was not verified by experimental 
data. Therefore, the effects of c.3444+1G>A on splicing were reexamined by in silico and  
in vitro experiments. 
 
3.1.1 In silico splicing analysis of c.3444+1G>A 
 
In order to reconstruct the mechanism by which c.3444+1G>A could lead to truncation of the 
last 28 aa of CNGB1a, in silico analysis was performed using the NNSplice 0.9 splice site 
prediction software (http://www.fruitfly.org/seq_tools/splice.html) (Fig. 7). The DNA sequence 
used for this analysis starts with exon 32 and ends with the stop codon of CNGB1. A 
plausible explanation for the splicing scenario proposed by the original study would be the 
use of cryptic donor sites.  
 
 
Fig. 7 Donor site prediction of a CNGB1 genomic DNA fragment encompassing exon 32-33 
(3911 bp in length) using the NNSplice 0.9 splice site prediction software 
(http://www.fruitfly.org/seq_tools/splice.html). The respective positions of the predicted donor sites 
on genomic DNA are shown as blue arrowheads, the position of the c.3444+1G>A mutation is marked 
by a black arrowhead. In the lower part of the figure, start and end positions of the DNA sequence 
flanking the donor site as well as the corresponding score values are shown. Donor site is highlighted 
in upper case (blue font). 
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As shown in Fig. 7, the DNA sequence analysed herein harbours seven potential cryptic 
donor sites. Use of the cryptic donor site in exon 33 would indeed delete the sequence that 
encodes the last 28 aa. However, it would also lead to retention of intron 32. In this case, due 
to an intronic stop codon 171 bp after exon 32, the corresponding protein would lack all 97 
aa encoded by exon 33. 
 
3.1.2 Creation of wild type and mutant minigene constructs 
 
In conclusion, no possible splice scenario could be reconstructed that would give rise to the 
deletion of only the last 28 aa of the CNGB1 protein. Therefore, the splicing of the construct 
containing the c.3444+1G>A mutation was analysed experimentally. For this purpose, a DNA 
fragment starting from the last 55 bp of intron 30 and ending with the last 42 bp after the stop 
codon within exon 33 of CNGB1 was amplified by PCR from human genomic DNA and was 
sequenced. For cloning convenience, a 7.1 kb fragment of intron 31 flanked by XbaI sites 
was deleted. The final 6.4 kb minigene construct was subcloned into the pcDNA3 vector. The 
c.3444+1G>A mutation was inserted using standard site directed mutagenesis (Fig. 8).  
 
 
 
Fig. 8 Schematic representation of the minigene construct used for the exon trapping 
experiment showing the position of the deleted intronic XbaI-fragment. pcDNA3 vector backbone 
sequence is depicted in green.  
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3.1.3 Exon trapping experiments in HEK293T cells 
 
Wild type and mutant minigene constructs were transfected in HEK293T cells and after 48 h, 
cells were harvested followed by total RNA isolation. After cDNA synthesis and PCR 
amplification with vector specific primers the splicing products derived from the minigenes 
were sequenced (Fig. 9).  
 
 
 
 
Fig. 9 Exon trapping experiment from transfected HEK293T cells. On the left, revese transcriptase 
PCR from HEK293T cells transfected with mutant and wild type minigene constructs is depicted. The 
electropherogram for the c.3444+1G>A mutant shows the skipping of exon 32. Wild type construct 
was spliced correctly (data not shown). On the right, schematic representation of the splice products is 
shown. The length of the respective PCR products is indicated by double arrows. WT: wild type, Mut: 
c.3444+1G>A mutation. 
 
As shown in the upper figure, the c.3444+1G>A mutation results in skipping of exon 32 
thereby leading to a frameshift after exon 31. As a result, the regular coding region of 
CNGB1a stops after amino acid 1075 followed by 68 unrelated amino acids. The deleted part 
of CNGB1a encompasses 170 aa and covers the complete distal C-terminus including the 
last 10 aa of the αC helix within the CNBD (Fig. 10). 
 
 
 
 
 
 
 
 26 Results 
 
 
Fig. 10 Schematic comparison of the WT and mutant protein demonstrating the lack of the 
entire distal C-terminus and the last 10 aa of the αC helix in the context of the c.3444G>A 
mutation. Skipping of exon 32 causes a frameshift which results in addition of 68 unrelated amino 
acids after aa position 1075 of the CNGB1a protein (highlighted in grey). The numbers represent the 
length of the respective proteins (1245 aa for WT and 1143 for the mutant). S1-S6: transmembrane 
segments. 
 
3.1.4 In vitro expression of wild type and mutant rod CNG channels 
 
To investigate the consequences of skipping of exon 32 on the full length protein the human 
full-length mutant CNGB1a was coexpressed in HEK293T cells with human CNGA1. The  
full-length mutant CNGB1a cDNA was obtained by deleting the exon 32 of the full-length wild 
type CNGB1 cDNA. For western blotting experiments membrane proteins were isolated from 
HEK293T cells transfected with CNGA1 and wild type or mutant CNGB1a.  
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Fig. 11 Western blot of membranes isolated from HEK293T cells transfected with CNGA1 and 
wild type or mutant CNGB1a probed with anti-B1 (top panel) or anti-ATPase (bottom panel). The 
weaker expression of the mutant protein was normalized in the presence of the proteasome inhibitors 
MG-132 and ALLN. The blot was probed with an antibody directed against the N-terminus of CNGB1a 
(PPc6N, [23]). As loading control anti-ATPase antibody (1:1000, clone α6F, developed by D.M. 
Fambrough, obtained from the Developmental Studies Hybridoma Bank, Iowa) was used. In 
proteasome inhibition experiments MG-132 and ALLN (25 µM each, Calbiochem) were added directly 
to the cells sixteen hours prior to harvesting. 
 
As shown in Fig. 11, in the western blot analysis using an antibody directed against the N-
terminus of CNGB1a the expected 240 kDa band for the wild type CNGB1a could be 
detected. As anticipated, the mutant CNGB1a protein was smaller than the wild type 
counterpart. Furthermore, the expression level of the mutant CNGB1a was considerably 
reduced compared to the wild type CNGB1a. Since this difference in expression could be 
reversed by the addition of the proteasome inhibitors MG-132 and ALLN, respectively, the 
conclusion can be drawn that the mutant protein is partially degraded by the proteasome.  
In summary, the c.3444+1G>A mutation was shown to result in skipping of exon 32 on 
mRNA level thereby leading to a frameshift after exon 31 and a premature stop codon. On 
protein level this mutation gives rise to deletion of the last 170 aa of the mutant protein 
including 10 aa of the αC helix within the CNBD. Finally, in vitro results from HEK293T cells 
after coexpression of the mutant CNGB1a with CNGA1 have shown that the mutant CNGB1a 
is prone to proteasomal degradation.  
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3.2 Functional analysis of the G993V mutation in CNGB1 
 
As described in chapter 1.7, this part of the study addressed the role of the CNGB1a subunit 
on the activation process of the heteromeric rod CNG channel. For this purpose, a naturally 
occurring point mutation in the human CNGB1 gene that leads to a glycine-valine exchange 
at position 993 in the CNBD of CNGB1a (CNGB1aGV) was analysed. This mutation was 
identified in a French family suffering from retinitis pigmentosa (RP) [31].  
 
 
3.2.1 In silico analysis  
 
To examine the effects of the G993V mutation computationally, two approaches were 
performed. The first approach included the analysis of the evolutionary conservation of the 
glycine residue at position 993 among different proteins known to have very similar cyclic 
nucleotide-binding domain structure (see chapter 1.4.1). In the second approach, to analyse 
the consequences of the GV mutation on the conformation of the CNBD in CNGB1a, a 
molecular dynamics (MD) simulation was performed by the group of Prof. Wanner, 
Department of Chemistry, Ludwig Maximilians Universität München (Fig. 12). As template 
coordinates the crystal structure of the CNBD of the sea urchin HCN channel was used [50]. 
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Fig. 12 In silico analysis of the G993V mutation. A) Sequence alignment of the β2-αC region of the 
CNBD of human CNGB1a, human CNGA1, E. coli CAP, sea urchin (sp) HCN1 and human PKG1. 
Invariant residues are highlighted in red. The invariant glycine residue within the β2-β3 loop that is 
mutated to valine (GV mutation) in the CNGB1a subunit of RP patients is marked with an asterisk. 
Residues identified in the crystal structure of HCN channel CNBDs to participate in cyclic nucleotide-
binding [51] are marked with arrowheads. B) Predicted structure of the cGMP binding pocket of 
CNGB1a (left) and CNGB1aGV (right). The sequences were threaded onto the crystal structure of the 
CNBD of spHCN [51] by using Modeller [52] and analysed using molecular dynamics simulations. The 
glycine and the valine residue in the β2-β3 loop of CNGB1a and CNGB1aGV, respectively, are 
represented as space filling spheres. Residues in the β6 and β7 strands as well as in the C helix 
participating in cGMP-binding are shown as sticks. Only one monomer is shown for clarity.  
 
As outlined in Fig. 12, the GV mutation in the CNBD of CNGB1a refers to a glycine residue in 
the β2-β3 connecting loop that is strictly conserved throughout evolution. The available 
crystal structures of CNBDs indicate that the glycine is not directly involved in cGMP binding 
but that it is essential for the integrity of the overall fold of the CNBD [53]. As is evident from 
Fig. 12, the GV mutation induces major structural alterations in the CNBD. These 
rearrangements lead to the occlusion of the cGMP binding cavity and a reduction of the 
cGMP binding site volume.  
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3.2.2 Expression of CNGA1GV 
 
Based on the findings from the in silico analysis, the GV mutation could have the potential to 
impair cGMP binding and, hence, channel activation. To test this hypothesis the GV mutation 
was introduced into the CNBD of CNGA1 and the expression as well as the 
electrophysiological properties of the mutant CNGA1 were analysed (Fig. 13).  
 
Fig. 13 CNGA1GV is expressed on the plasma membrane of transfected HEK293 cells. A) Top 
panel: Western blot of membranes from HEK293 cells transfected with CNGA1-CFP or CNGA1GV-
CFP, respectively. The blot was probed with anti-GFP antibody. Bottom panel: membranes probed 
against the ATPase α subunit. (B) Representative current traces elicited by 1 mM cGMP and voltage 
steps (2 s each) to -80 mV and +80 mV in excised patches from HEK293 cells expressing CNGA1 
(A1), or CNGA1GV (A1GV), CNGA1GV/CNGB1a (A1/B1a) and CNGA1GV/CNGB1b (A1/B1b). 
 
As shown in Fig. 13, the GV mutation had no consequences on protein expression level. 
However, as predicted, CNGA1GV channels were functionally inactive even in the presence 
of 1 mM cGMP. Coexpression of CNGB1a or the olfactory CNGB1b subunit that lacks the 
GARP domain failed to rescue channel activity. 
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3.2.3 Electrophysiological measurements of heteromeric CNGA1/CNGB1aGV 
channels 
 
Next step was to analyse the effects of the GV mutation in CNGB1a on the heteromeric 
channel complex. To this end, CNGA1 was coexpressed together with either wild type or 
mutant CNGB1a and the properties of the resulting currents were compared to currents 
induced by CNGA1 alone (Fig. 14).  
 
 
 
Fig. 14 Electrophysiological characterisation of heteromeric CNGA1/CNGB1GV channels. 
Single-channel currents induced at +60 mV by 3 µM cGMP in excised patches of HEK293 cells 
transfected with CNGA1 (A1), CNGA1/CNGB1a (A1/B1a) or CNGA1/CNGB1aGV (A1/B1aGV). (B) 
Current-voltage relation of A1, A1/B1a and A1/B1aGV in the presence of 2 mM Ca2+ and 1 mM Mg2+ in 
the extracellular solution. Current was normalized to the current at +60 mV. (C) Inhibition of A1, 
A1/B1a and A1/B1aGV currents by 100 µM Ca2+ / 250 nM calmodulin in the bath solution. Currents 
were induced at +80 mV by 100 µM cGMP. (D) L-cis-diltiazem (10 µM) block of A1, A1/B1a and 
A1/B1aGV currents induced by 300 µM cGMP at +80 mV. Number of experiments is given in brackets. 
 32 Results 
 
Surprisingly, currents obtained after coexpression of CNGA1 and CNGB1aGV did not exhibit 
typical CNGB1a-mediated features but were indistinguishable from currents of homomeric 
CNGA1 channels (Fig. 14 A-D). While single channel currents of heteromeric CNG channels 
are characterised by very brief open-closed transitions (single channel flicker), single channel 
currents obtained after coexpression of CNGA1 and CNGB1aGV displayed long openings 
which is typical of homomeric CNGA1 channels (Fig. 14 A). In addition, the strong outwardly-
rectifying current-voltage relation of channels obtained after coexpression of CNGA1 and 
CNGB1aGV in the presence of extracellular divalent ions was virtually identical to that of the 
homomeric CNGA1 channel, but clearly differed from that of weakly rectifying wild type 
heteromeric channels (Fig. 14 B). In contrast to wild type CNGB1a, CNGB1aGV did not 
increase Ca2+/CaM sensitivity if coexpressed with CNGA1 (Fig. 14 C). Probably the most 
indicative feature resulting from the presence of the CNGB1 subunit is the generation of a 
high affinity site for block by L-cis-diltiazem [26]. Indeed, unlike homomeric CNGA1 channels, 
heteromeric CNGA1/CNGB1a channels were efficiently blocked by this drug. By contrast, 
currents obtained after coexpression with CNGB1aGV were not sensitive to L-cis-diltiazem 
(Fig. 14 D).  
 
3.2.4 Coassembly and cell surface expression of CNGA1/CNGB1aGV heteromers 
 
The total absence of CNGB1a-mediated properties in conjunction with the complete 
correspondence with the biophysical properties of homomeric CNGA1 currents indicated that 
currents measured after cotransfection of CNGA1 and CNGB1aGV were purely caused by 
CNGA1 homomers. A possible explanation for this result would be that after cotransfection of 
CNGA1 and CNGB1aGV only homomeric CNGA1 channels are present in the membrane 
because CNGA1/CNGB1aGV heteromers are not assembled, are rapidly degraded or fail to 
be transported to the plasma membrane. To test these options, biotinylation,  
co-immunoprecipitation and FRET experiments on CNGA1/CNGB1GV heteromers were 
performed (Fig. 15). 
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Fig. 15 Cell-surface expression and assembly of CNGA1/CNGB1GV heteromers.  A) Biotinylation 
of non-transfected (ø), CNGA1/CNGB1a (WT) and CNGA1/CNGB1aGV (GV) transfected HEK293 
cells probed with anti-B1 (top panel) or anti-tubulin (tub, bottom panel) antibodies. B) Co-
immunoprecipitation (co-IP) from lysates of HEK293 cells co-transfected with myc-tagged CNGA1 and 
wild type CNGB1a or CNGB1aGV, respectively. Top panel: immunoprecipitation (IP) using anti-myc 
for pulldown and anti-B1 for detection. Bottom panel: Western blots showing the starting material for 
the co-IP probed with anti-myc (left) or anti-B1 antibodies (right). C) N-FRET ratios calculated from 
HEK293 cells co-transfected with CNGA1-CFP and YFP-CNGB1a (WT) or YFP-CNGB1aGV, 
respectively. HEK293 cells transfected with CFP and YFP-CNGB1a or a CFP-YFP tandem were used 
for the calculation of negative (neg) and positive (pos) control N-FRET values, respectively. Number of 
experiments is given in brackets. 
 
As is evident from Fig. 15 A, cell surface biotinylation experiments using membrane 
impermeable amine-reactive biotin showed that both wild type and mutant channels were 
present at the membrane of transfected cells. In addition, CNGB1aGV could be co-
immunoprecipitated with CNGA1 indicating the formation of stable heteromers (Fig. 15 B). 
Finally, assembly of CNGA1 with CNGB1aGV was also verified by Förster resonance energy 
transfer (FRET) (Fig. 15 C). 
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3.2.5 Identification of inhibitory domains in CNGB1a 
 
Another explanation for the selective detection of homomeric CNGA1 currents in HEK293 
cells transfected with CNGA1 and CNGB1aGV may be that homomeric and mutant 
heteromeric CNG channels do coexist in the plasma membrane but in contrast to homomeric 
CNGA1 channels mutant heteromers cannot be activated by cGMP and, thus, do not 
contribute to any measurable current. In an attempt to identify structural determinants 
conferring an inhibitory action of CNGB1aGV the GV mutation was introduced into the 
olfactory CNGB1b subunit that differs from CNGB1a by lacking the GARP domain. This new 
mutant was coexpressed with CNGA1 and patch clamp recordings were performed (Fig. 16).  
 
 
 
Fig. 16 Identification of N-terminus of CNGB1a (herein referred to as “GARP domain”) as the 
inhibitory domain. The GV mutation does not impair channel function in the context of the olfactory 
CNGB1b isoform lacking the GARP domain. Top panel: Schematic representation of CNGB1a and 
CNGB1b subunits. The position of the GV mutation is highlighted by an asterisk. Amino acid position 
555 is highlighted since starting from this position CNGB1a and CNGB1b are identical. Bottom panel: 
Summary graph showing the L-cis-diltiazem sensitivity of various homo- or heteromeric channels. 
Currents were elicited by 300 µM cGMP at +80 mV. L-cis-diltiazem was used at 50 µM for A2, A2/A4, 
A2/A4/B1b and A2/A4/B1bGV and at 10 µM for all other channels.  
S1-S6, transmembrane domains; CNBD, cyclic nucleotide-binding domain. Scale bar marks 100 
amino acids. 
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Surprisingly, as shown in Fig. 16, L-cis-diltiazem sensitive currents were now obtained with 
both wild type and mutant CNGB1b subunits. Sensitivity to L-cis-diltiazem was also 
consistently observed when the GV mutation was introduced into the native olfactory CNG 
channel complex consisting of CNGA2/CNGA4 and CNGB1b. Like for CNGA1 the wild type 
but not the mutant CNGB1a subunit induced L-cis-diltiazem sensitivity when coexpressed 
together with CNGA2. These results indicated that the GARP domain mediates the dominant 
negative effect of CNGB1aGV. To identify the inhibitory determinants within the GARP 
domain, a systematic mutation screening was performed by deleting specific regions of this 
domain. The respective constructs were coexpressed with CNGA1 in HEK293 cells followed 
by electrophysiological measurements of L-cis-diltiazem mediated CNG current inhibition. 
Fig. 17 shows a summary of the most important mutation constructs analysed in this 
approach.   
 
 
Fig. 17 Mutagenesis screen within the GARP domain. Top panel: cartoon showing the CNGB1a 
subunit. The two sequences conferring most of the inhibitory effect are highlighted in grey. Bottom 
panel: graphic overview on N-terminal truncation constructs (left) and summary graph comparing the 
effect (% inhibition) of 10 µM L-cis-diltiazem on cGMP currents (300 µM, +80 mV, right) measured 
from HEK293 cells co-transfected with CNGA1 and various N-terminal truncated CNGB1aGV mutants 
or a B1aGV chimera in which the N-terminus was replaced by the yellow fluorescent protein (YFP). 
Number of experiments is given in brackets. * = p < 0.05, ** = p < 0.01, *** = p < 0.005. Scale bar 
marks 100 amino acids. S1-S6, transmembrane helices. 
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As is evident from Fig. 17, study of mutants with deletions in the GARP domain identified two 
regions (residues 214-253 and 364-481) of CNGB1a that confer most of the inhibitory effect. 
Fusion of an unrelated peptide (YFP) to the N-terminus of CNGB1bGV did not result in 
channel inhibition excluding unspecific effects which could be mediated merely by the length 
of the N-terminal domain.  
 
As described in chapter 2.1.12, the experiments shown so far were obtained using rat 
CNGB1a and bovine CNGA1 channels. To examine if inhibitory effects of the GARP domain 
can be obtained using CNG channels from other species, the GV mutation was introduced 
into the human CNGB1a (hCNGB1a) subunit containing and lacking the GARP domain. After 
coexpression with human CNGA1 (hCNGA1), L-cis-diltiazem sensitivity was measured for 
these channels. The results are shown in Fig. 18. 
 
 
Fig. 18 Effects of the GV mutation and of the GARP domain on human rod CNG channels. 
Percent inhibition by 10 µM L-cis-diltiazem of currents obtained after cotransfection of human CNGA1 
with wild type or mutant human CNGB1a lacking or containing the GARP domain in presence of 300 
µM cGMP. hB1a#452-1245 corresponds to the rat CNGB1a construct B1a#556-1339 (see i.e. Fig. 17 
and Fig. 19). Number of experiments is shown in brackets.  
 
As shown in Fig. 18 the GV mutation as well as the GARP domain of the human rod 
channels show very similar electrophysiological characteristics regarding the L-cis-diltiazem 
sensitivity as described above for rat CNGB1a and bovine CNGA1 channels, respectively. 
This indicates that the observed effects of the GARP domain represent a general mechanism 
transferable to rod channels of all species.    
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3.2.6 Coexpression of GARP as soluble protein  
 
To test whether the GARP domain can act inhibitory as an autonomous protein it was 
coexpressed as separate protein (B1a#1-555) together with CNGA1 and a CNGB1a 
truncation construct (B1a#556-1339, see cartoon in Fig. 19 A).  
 
 
 
Fig. 19 GARP acts as an autonomous unit when coexpressed as soluble protein. A) Schematic 
representation of the truncated B1a#556-1339 GV channel and the protein corresponding to the 
GARP domain. B) Percent inhibition by 10 µM L-cis-diltiazem of currents obtained after cotransfection 
of CNGA1 with various CNGB1a-derived constructs as indicated. Number of experiments is given in 
brackets. ** = p < 0.01 
 
Currents obtained from the coexpression of CNGA1 with B1a#556-1339 were sensitive to L-
cis-diltiazem. By contrast, coexpression of the GARP domain, CNGA1 and CNGB1a#556-
1339GV again abolished the block by L-cis-diltiazem (Fig. 19 B). This finding suggested that 
the GARP domain exerts its inhibitory effect even if it is not covalently linked to the CNGB1 
core.  
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To test if the inhibitory effect of GARP is mediated by direct binding of this domain to the 
CNGB1a or CNGA1 subunit, co-imunoprecipitation experiments were performed (Fig. 20).   
 
 
 
Fig. 20 Co-immunoprecipitation of the GARP domain (B1a#1-555) with CNGA1 (myc-tagged) or 
CNGB1a#556-1339 WT or GV. A) Schematic representation of the truncated B1a#556-1339 GV 
channel and the protein corresponding to the GARP domain (B1a#1-555) and binding sites of the B1a-
specific antibodies used for experiments shown in B and C, respectively. B) Co-IP using the anti-myc 
antibody capable of the immunoprecipitation of myc tagged CNGA1 C) Co-IP using anti CNGB1 
directed against the C-terminus of this protein.  
1, coexpression of A1 + B1a#1-555; 2, A1 + B1a#1-555 + B1a#556-1339; 3, A1 + B1a#1-555 + 
B1a#556-1339GV; 4, B1a#1-555 + B1a#556-1339. Anti-B1, rabbit polyclonal antibody directed against 
the C-terminus of CNGB1a. PPc6N, rabbit polyclonal antibody directed against the N-terminus of 
CNGB1a. IP, immunoprecipitation.  
 
 
As is evident from Fig. 20 B and C, the soluble GARP domain formed stable protein 
complexes with both CNGA1 and either mutant or wild type CNGB1a#556-1339. Therefore, 
the inhibitory action of GARP on the channel is probably due to direct binding of this domain 
to the channel core.  
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3.2.7 Role of a functional CNBD of CNGB1 for CNG channel activation 
 
Results shown in Fig. 20 indicate that the GARP domain binds to both CNGA1 and CNGB1 
subunits in the heteromeric CNG channel complex. In wild type heteromers the identified 
GARP-channel interaction does not interfere with cGMP-dependent activation. By contrast, in 
the presence of the GV mutation the GARP domain completely shuts down channel activity. 
Based on MD simulations (Fig. 12) the conclusion can be drawn that the inhibitory effect of 
GARP may be causally linked to the inability of CNGB1aGV to bind cGMP. To test this 
hypothesis the effects of GARP in the presence of a double mutation in the β7 strand of the 
CNBD (R1042E and T1043A, herein after referred to as RT>EA) that is well known to abolish 
cyclic nucleotide-binding in CNG and HCN channels [13, 51] were analysed (Fig. 21).  
 
 
 
Fig. 21 Summary graph comparing the L-cis-diltiazem sensitivity of heteromeric channels 
containing wild type and cyclic nucleotide-binding deficient (RT>EA) B1a or B1b subunits. 
RT>EA: substitution of arginine and threonine within the β7-sheet of the CNBD by glutamate and 
alanine, respectively. Number of experiments is given in brackets. 
 
As anticipated, in the backbone of CNGB1b the double mutation did not interfere with the 
formation of functional heteromeric (L-cis-diltiazem sensitive) channels. However, when 
introduced into CNGB1a the mutation fully blocked heteromeric channel activity and only the 
residual homomeric (L-cis-diltiazem insensitive) CNGA1 channel was detected (Fig. 21). 
Thus, with respect to its functional effect on heteromeric channels containing or lacking the 
GARP domain, the RT>EA mutation was indistinguishable from the GV mutation.  
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3.2.8 Opening probability of channels containing or lacking the GARP domain  
 
The experiments shown so far indicated that the GARP domain blocks gating of heteromeric 
CNG channels which contain a CNGB1 subunit deficient for cGMP binding. The next 
question was whether the GARP domain could also interfere with the gating of wild type 
heteromeric channels containing a functional CNBD. If so, differences in some 
electrophysiological parameters should also be detectable when comparing wild type 
CNGA1/CNGB1a with CNGA1/CNGB1a#556-1339 channels lacking GARP. To test one of 
these parameters, cGMP sensitivity for both channel types was measured but no apparent 
differences were detectable in this experiment (data not shown). However, the analysis of the 
maximal open probability for cGMP (Pmax) showed that heteromeric channels containing the 
GARP domain had a significantly lower Pmax compared to channels lacking this domain  
(Fig. 22). 
 
 
Fig. 22 Summary graph comparing the maximal open probability for cGMP (Pmax) of wild type 
homomeric A1, heteromeric A1/B1a and A1/B1a#556-1339 channels. (Pmax(cGMP): CNGA1/CNGB1a 
= 0.86 ± 0.02 (n=7), CNGA1/CNGB1a#556-1339 = 0.93 ± 0.02 (n=11), p < 0.05). 
 
The finding that the presence of the GARP domain lowers the opening probability of CNG 
channels strongly supports the notion that the GARP domain acts as gating inhibitor in the 
rod photoreceptor channel.  
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Based on the results described in chapters 3.2.1-3.2.8, a final model was worked out in order 
to explain the observed effects (Fig. 23). 
 
 
 
Fig. 23 Model of the action of the GARP domain in wild type and mutant heteromeric CNG 
channels. A) In wild type rod channels, GARP domain serves as a gating inhibitor. Binding of cGMP 
to CNGB1a subunit releases the tonic inhibition mediated by the GARP domain giving rise to channel 
opening. For reasons of clarity, the contempable intermediates (i. e. if only one or two cGMP are 
bound to CNGA1) are not included in this model. B) GV mutation in CNGB1a probably prevents cGMP 
binding to this subunit. Therefore, the tonic inhibition of GARP may not be released and the channels 
remain in the closed state. C) If the GARP domain is removed from the mutant CNGB1 subunit the 
heteromeric channels are able to open in the presence of cGMP for two reasons. The first reason is 
the fact that binding of two cGMP was shown to be sufficient for maximal opening of olfactory CNG 
channels (see chapter 1.4.2). The second reason is the absence of the GARP domain as gating 
inhibitor.   
 
The final conclusion that can be drawn from the model shown in Fig. 23 is that binding of 
cGMP to the CNGB1a subunit serves as a prerequisite for opening of rod CNG channels 
because of the inhibitory effect of the GARP domain on the gating process.  
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4 Discussion 
 
4.1 Splicing analysis of the c.3444+1G>A mutation in CNGB1 
 
 
In this part of the study, the pathogenic effect of a previously reported splice site mutation in 
CNGB1 could be verified experimentally. Initial in silico analysis suggested that no splicing 
scenario would lead to “a frameshift and truncation of the last 28 aa” of CNGB1a as 
postulated by the original study [32]. Using in vitro exon trapping experiments it could be 
shown that this mutation gives rise to skipping of exon 32. However, due to the limitation of 
exon trapping experiments, the possibility that in photoreceptors the mutation may have 
other effects on splicing cannot be completely excluded.  
Based on the results obtained in HEK293T cells in this study, the c.3444+1G>A mutation 
may lead to the RP phenotype by negatively affecting the  
i) Channel expression. The expression of the mutant CNGB1a is compromised by the action 
of the proteasome. This may also be the case in rod photoreceptors resulting in reduction or 
in complete loss of channel. Mutations that result in premature stop codons are known to 
trigger nonsense mediated mRNA decay (NMD) [54]. Since skipping of exon 32 gives rise to 
a premature stop codon, it seems possible that c.3444+1G>A mutant transcripts are affected 
by NMD in vivo, which would also negatively affect channel expression.  
(ii) Channel targeting. Recently, it has been shown that the distal C-terminus of CNGB1a 
contains an ankyrin G binding motif responsible for the proper targeting of the channel to rod 
outer segments [17]. This domain is located within the deleted sequence in the mutant 
CNGB1a. Thus, if the channel is expressed, its targeting to rod outer segments may be 
affected by the mutation.  
(iii) Channel function. It has been shown that the structural integrity of the αC helix of the 
CNBD is crucial for proper channel gating [48, 55, 56]. Since the c.3444+1G>A mutation 
results in loss of the last 10 aa of the αC helix, the mutant channel, even if expressed at 
normal levels in rod outer segments, would be most probably non-functional. Which of these 
parameters (and to which extent) contributes to the disease in affected patients remains to 
be determined.  
A comparison of the clinical investigations performed on patients which are affected by the 
c.3444+1G>A mutation with those affected by the c.2978G>T (p.G993V) mutation would be 
helpful in order to gain some insights into functional consequences of these two mutations  
in vivo. However, since clinically relevant parameters (i. e. electroretinogram) were examined 
only for one patient in the respective studies [31, 32], this comparison appears to be rather 
unreasonable at this point.  
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4.2 Functional analysis of the G993V mutation in CNGB1 
 
In this part of the study the role of the CNGB1a subunit in the cGMP-dependent activation 
process of the rod photoreceptor CNG channel was examined. The CNBD of CNGB1a 
contains all canonical residues required for high affinity cGMP binding [26, 47, 57-59] and 
was shown in photoaffinity labeling experiments to bind cGMP [60]. While these findings 
suggest that CNGB1a contributes to channel activation, the analysis of the role of CNGB1a 
in this process has been hampered by the fact that CNGB1a does not form functional 
homomeric channels. The results of this study have shed new light on this issue by analyzing 
a naturally occurring mutation in CNGB1a of RP patients (GV mutation) that impairs the 
structural integrity and/or cGMP binding capability of the CNBD. It was found that this 
mutation exerts a strong dominant negative effect leading to a complete functional silencing 
of heteromeric channels. Surprisingly, however, the impact of the GV mutation was strictly 
dependent on the presence of the proximal part of the N-terminus of CNGB1a (GARP 
domain) and was not observed for the short CNGB1b subunit. Unlike homomeric CNGA1 or 
heteromeric CNGA1/CNGB1aGV channels, channels containing CNGB1bGV displayed high 
sensitivity to block by L-cis-diltiazem which is the pharmacological hallmark of a functional 
CNGB1 subunit. The different effect of the two CNGB1 isoforms was also observed for 
another extensively characterised mutation impairing cGMP binding (RT>EA mutation) and 
was found when CNGB1a/b were assembled with another CNG A-subunit (CNGA2). Two 
important conclusions can be drawn from these findings. Firstly, in the absence of the GARP 
domain binding of cGMP to CNGB1 is not required for principal activation of heteromeric 
channels. This is in good agreement with a recent study showing that in the homomeric 
CNGA2 channel only two subunits of the tetrameric complex must bind a cyclic nucleotide to 
fully activate the channel [20]. Secondly, however, the presence of the GARP domain 
fundamentally interferes with the activation process, transforming cyclic nucleotide-binding to 
CNGB1 from a non-essential process to a prerequisite of channel activation. An inhibitory 
effect of the GARP domain on channel gating is supported by the finding that wild type rod 
channels have a lower open probability than rod channels lacking the GARP domain in 
CNGB1a. Therefore, it can be concluded that GARP is an autoinhibitory domain that controls 
channel activation. In the native rod CNG channel the GARP domain interacts with the 
channel complex (CNGA1 and CNGB1). Binding of cGMP to CNGA1 and CNGB1a relieves 
the inhibitory effect of GARP leading to channel opening. In channels containing a CNGB1a 
subunit that is deficient for cGMP binding the autoinhibitory impact of GARP cannot be 
removed, and CNGB1a stays locked in its closed state. This prevents the opening transition 
of the tetrameric channel complex even if cGMP is bound to the three CNGA1 subunits. In 
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the absence of the GARP domain there is no longer a constraint on channel gating. Now, 
binding of cGMP to the CNGA1 subunits is sufficient for full activation. The exact molecular 
mechanism underlying the action of the GARP domain remains to be determined. However, 
the co-immunoprecipitation experiments indicate that GARP can directly bind to both CNGA1 
and CNGB1 suggesting that a direct protein-protein interaction underlies the effect of GARP. 
The GARP domain was shown to have a flexible, largely unordered structure in solution [61]. 
It seems possible that like other unstructured proteins such as bacterial FlgM [62] GARP can 
gain structure in the presence of specific binding partners. The identification of two 
sequences within the GARP domain that are responsible for most of its inhibitory effect 
supports the notion that GARP specifically interacts with the CNG channel. However, 
deletion of one of these regions alone was not sufficient to prevent the inhibitory effect 
(chapter 3.2.5). Since in this study GARP was shown to interact with both CNGB1 and 
CNGA1 it seems plausible that one of these regions is involved in binding to CNGB1, the 
second one for binding to CNGA1. Therefore, both interactions have to be disrupted to 
completely remove the inhibitory effect mediated by the GARP domain.  
One common feature of the two inhibitory regions is the fact that they posses a unusually 
high percentage of negatively charged amino acids, especially glutamate. This part of the 
GARP domain may interfere with the N-terminus of CNGA1 that contains a positively 
charged lysine-rich region. The αC helix of CNGB1 also harbours a high amount of positively 
charged residues making it a good candidate for the interaction with the GARP domain. 
However, the exact mechanism how the negative charge interferes with channel gating is 
beyond the scope of this study and remains to be determined. 
In this study it could also be shown that GARP acts inhibitory if expressed as separate 
protein indicating that it forms an autonomous folding unit. The latter finding is important 
since it indicates that soluble GARP1 and GARP2 that are coexpressed together with 
CNGB1a in rod outer segments also can inhibit channel gating. It was proposed that the 
GARP domain of CNGB1a tethers the heteromeric CNG channel to the disc rim of outer 
segments by interacting with peripherin-2 [35, 61]. It is not known whether or not the GARP-
peripherin-2 interaction competes with the interaction between GARP and the channel 
complex. However, even if this is the case, free soluble GARPs could still bind to the 
channel. This is particularly relevant for the major GARP isoform, GARP2, that contains one 
of the sequences conferring channel inhibition and is present in about 25 fold molar excess 
with respect to CNGB1a [61].  
Currently, one can only speculate on physiological implications arising from the GARP-
mediated inhibition of the unliganded CNG channel. Given that homomeric CNGA1 channels 
have a very small but detectable spontaneous open probability [63, 64] the inhibitory effect of 
GARP may have evolved to reduce current noise resulting from openings of CNG channels 
Discussion 45  
in the absence of cGMP to the lowest possible levels. In rod outer segments only 
approximately 1 % of CNG channels are open in the dark and this percentage even 
decreases upon light-induced cGMP hydrolysis [65]. Thus, it is tempting to speculate that 
GARP domains to some extent contribute to the low percentage of open CNG channels and, 
hence, increase the sensitivity and precision of rod phototransduction. In agreement with this 
hypothesis, GARP domains are not present in cone photoreceptors that are much less 
sensitive to light.  
In CNGB1a/CNGB1b KO mice [28, 29] GARP1 and GARP2 remain intact and the 
morphology of the rod photoreceptors is not affected by the lack of the CNGB1a subunit 
alone. In contrast, CNGB1 KO mice deficient for both CNGB1a and GARPs show an 
impaired structure of outer segments and a spoiled discs morphogenesis [36]. This supports 
the assumption that GARPs also function as scaffolding proteins. However, since no specific 
GARP1 or GARP2 KO mice are available so far, synergistic effects contributing to this 
phenotype cannot be excluded. Potential mutations within the GARP region in the CNGB1 
locus have been identified in some patients suffering from autosomal recessive RP [36]. 
However, the affected families were too small to establish a causative relationship between 
the mutation and the disease.   
Finally, this part of the study explains the clinical phenotype of patients carrying the GV 
mutation. Since heteromeric CNGA1/CNGB1aGV channels are inactive, rod photoreceptors 
of the patients cannot respond to light-induced changes in the cGMP concentration. 
Importantly and unlike in HEK293 cells, in rod photoreceptors CNG channel activity cannot 
be conferred by homomeric CNGA1 channels since these channels are not targeted to outer 
segments [28, 36]. Thus, the phenotype of CNGB1aGV patients is equivalent to a total 
knockout of the CNGB1 subunit that also results in RP [28]. However, despite the fact that 
GV mutation does not show any trafficking defects in HEK293 cells as shown in  
Fig. 15, it cannot be excluded that this mutation may cause targeting deficits in vivo. 
Therefore, to finally confirm the effects of the GV mutation on the pathogenesis of RP in vivo, 
generation of appropriate knock-in animals would be inevitable.    
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5 Summary 
 
Rod CNG (cyclic nucleotide-gated) channels are heterotetrameric ion channels consisting of 
three CNGA1 and one CNGB1a subunit. To analyse the role of CNGB1a within the rod 
channel complex, functional consequences of two pathogenetically relevant mutations in the 
CNGB1 gene were characterised. Both mutations are associated with retinitis pigmentosa 
(RP), a congenital progressive eye disease.  
The first mutation (c.3999G>A) represents a donor site G>A transversion in exon 32 and has 
been proposed to result in a frameshift and truncation of the last 28 aa of the corresponding 
protein. However, no experimental evidence was provided for this assumption. Based on 
this, in a previous study it has been shown that last 28 aa of CNGB1a harbour a motif 
required for the proper targeting of this subunit to rod photoreceptor outer segments. This 
suggests defective targeting to be the major cause for the RP phenotype in affected patients. 
However, using exon trapping experiments, in this study it could be demonstrated that in 
contrast to the assumption described above the c.3999G>A mutation leads to skipping of 
exon 32 resulting in loss of the last 170 aa of CNGB1a. The 170 aa deletion covers the 
complete distal C-terminus including the last 10 aa of the important alpha αC helix within the 
CNBD. When expressed in HEK293T cells the corresponding mutant full-length CNGB1a 
subunit was susceptible to proteosomal degradation. Based on these findings, apart from the 
defective targeting other mechanisms may be responsible for the RP phenotype in affected 
individuals.  
The second RP associated mutation in the CNGB1 gene (c.2978G>T; p.G993V) represents 
a glycine to valine exchange at the highly conserved position 993 in CNGB1a. Molecular 
dynamics simulations suggested that this mutation leads to major rearrangements in the 
cyclic nucleotide-binding domain (CNBD) that impair cGMP binding. Heteromeric 
CNGA1/CNGB1aGV channels were normally expressed in the plasma membrane but were 
functionally inactive. However, when the long N-terminal glutamic acid-rich protein (GARP) 
domain of CNGB1a was deleted, functional heteromeric currents were obtained in the 
presence of the GV mutation. Coexpression of GARP as soluble protein with the mutant 
heteromeric channel complex again abolished channel function. Two regions within the 
GARP domain that confer most of the inhibitory effect could be identified, and it could be 
shown that the GARP domain directly binds to the heteromeric channel complex. In 
conclusion, in the absence of the GARP domain binding of cGMP to CNGB1 is not required 
for principal activation of heteromeric CNG channels. By contrast, in the native rod 
photoreceptor channel, cGMP binding to CNGB1a is indispensable to relief tonic inhibition 
imposed by the GARP domain. 
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Zusammenfassung 
 
Zyklonukleotid-aktivierte CNG (cyclic nucleotide-gated) Kanäle aus Stäbchen sind 
heterotetramere Ionenkanäle bestehend aus drei CNGA1 und einer CNGB1a Untereinheit. 
Zur Analyse der Rolle der CNGB1a Untereinheit im Stäbchen-Kanalkomplex wurden in 
dieser Arbeit die funktionellen Konsequenzen von zwei pathogenetisch relevanten 
Mutationen im CNGB1 Gen untersucht. Beide Mutationen sind mit Retinitis Pigmentosa (RP), 
einer erblichen degenerativen Augenerkrankung, assoziiert.  
Bei der ersten Mutation (c.3999G>A) handelt es sich um eine G>A Transversion an der 
Donorstelle des Exons 32. Diese Mutation wurde ursprünglich als eine 
Leserasterverschiebung kategorisiert und es wurde behauptet, dass sie in einer Trunkation 
der letzten 28 Aminosäuren des korrespondierenden Proteins resultiert. Basierend auf dieser 
experimentell nicht bestätigten These wurde in einer anderen Studie gezeigt, dass die letzten 
28 Aminosäuren von CNGB1a ein Motiv beherbergen, das für den Transport dieser 
Untereinheit in die Außensegmente der Stäbchen wichtig ist. Dies lässt vermuten, dass dem 
durch die c.3999G>A Mutation hervorgerufenen RP Phänotyp ein gestörter Transport von 
CNGB1a zu Grunde liegt. Mit Hilfe von Exon-Trapping-Experimenten konnte jedoch in dieser 
Arbeit nachgewiesen werden, dass im Gegensatz zur obigen Behauptung die c.3999G>A 
Mutation zum Überspringen von Exon 32 und infolgedessen zum Verlust der letzten 170 
Aminosäuren von CNGB1a führt. Die Deletion der 170 Aminosäuren umfasst den kompletten 
distalen C-terminus und die letzten 10 Aminosäuren der funktionell wichtigen αC-Helix 
innerhalb der CNBD. Die Expressionsstudie in HEK293T Zellen zeigte zudem, dass die 
mutierte CNGB1a Untereinheit für proteosomalen Abbau anfällig ist. Basierend auf diesen 
Experimenten kann geschlussfolgert werden, dass abgesehen vom gestörten Transport auch 
andere Mechanismen als Ursache von RP bei betroffenen Individuen in Frage kommen.  
Bei der zweiten mit RP assoziierten Mutation im CNGB1 Gen (c.2978G>T; p.G993V) handelt 
es sich um einen Glyzin zu Valin Austausch an der hochkonservierten Position 993 in 
CNGB1a. Ergebnisse der molekulardynamischen Simulation zeigten, dass diese Mutation zu 
einer ausgeprägten Umstrukturierung innerhalb der Bindedomäne für Zyklonukleotide 
(CNBD, cyclic nucleotide binding domain) führt, was mit einer Okklusion der cGMP 
Bindungstasche einherging. Trotz der im Vergleich zu Wildtyp-Kanälen unveränderten 
Plasmamembran-Expression waren die heteromeren CNGA1/CNGB1aGV Kanäle funktionell 
inaktiv. Nach Entfernung der langen N-terminalen glutamatreichen GARP (glutamic acid-rich 
protein) Domäne von CNGB1a erlangten die mutierten Kanäle jedoch ihre volle Funktion 
zurück. Koexpression der GARP Domäne als lösliches Protein mit dem mutierten 
heteromeren Kanalkomplex führte erneut zur Aufhebung der Funktion dieser Kanäle. Es 
wurden zwei Regionen innerhalb der GARP Domäne identifiziert, die für den größten Teil 
des inhibitorischen Effektes verantwortlich sind. Darüber hinaus konnte eine direkte Bindung 
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der GARP Domäne an den heteromeren Kanalkomplex nachgewiesen werden. 
Zusammenfassend lässt sich schlussfolgern, dass die cGMP Bindung an CNGB1 in 
Abwesenheit der GARP-Domäne für die prinzipielle Aktivierung heteromerer CNG Kanäle 
nicht notwendig ist. Im Gegensatz dazu stellt die Bindung von cGMP an CNGB1a im nativen 
Stäbchen-Kanäl die Voraussetzung für die Aufhebung der tonischen Inhibition dar, welche 
durch die GARP Domäne vermittelt wird. 
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7.1 Supplementary tables and figures 
 
           ATGTTGGGCTGGGTCCAAAGGGTGCTGCCTCAGCCTCCGGGGACCCCCCAGAAGACTGA 
1           M  L  G  W  V  Q  R  V  L  P  Q  P  P  G  T  P  Q  K  T  E 
 
          AGAGGGAGCAGGACCACAGCCAGAAACAGAGTCAAAGCCTGAGGCAAATCCACAACCCGA 
21          E  G  A  G  P  Q  P  E  T  E  S  K  P  E  A  N  P  Q  P  E  
 
          GCCAGAGGTTCAGCCGGAACCAGAGCCGGAACCGGAACCAGAGCCGGAACCGGAACCAGC 
41          P  E  V  Q  P  E  P  E  P  E  P  E  P  E  P  E  P  E  P  A  
 
          ACCTGAAGAGGCTGCACCAGAGGTCCAGACCCTGCCACCAGAGGAACCAGTGGAAGGAGA 
61          P  E  E  A  A  P  E  V  Q  T  L  P  P  E  E  P  V  E  G  E  
 
          GGATGTGGCTGAGGCTGGCCCTAGCCTTCAAGAGACCCAGGAAGCTGACCCTCCTCAGCC 
81          D  V  A  E  A  G  P  S  L  Q  E  T  Q  E  A  D  P  P  Q  P  
 
          CACCTCCCAGGCCCAGGTTGCTGTTGTCAAGGTGAACAGGCCCAGCTCCTGGATGTTGAG 
101         T  S  Q  A  Q  V  A  V  V  K  V  N  R  P  S  S  W  M  L  S  
 
          CTGGTTCTGGAAGGGCATGGAGAAGGTCGTGCCACAGCCTGTCTACAGCAGCAGTGGGGG 
121         W  F  W  K  G  M  E  K  V  V  P  Q  P  V  Y  S  S  S  G  G  
 
          CCAGAACCTGGCTGCCGGAGAGGGAGGCCCAGATCAGGATGGAGCACAGACCCTGGAGCC 
141         Q  N  L  A  A  G  E  G  G  P  D  Q  D  G  A  Q  T  L  E  P  
 
          CTGTGGCACTGGAGACCCAGGGTCTGAAGATGGCTCAGATAAAACTTCCAAGACTCAAGA 
161         C  G  T  G  D  P  G  S  E  D  G  S  D  K  T  S  K  T  Q  D  
 
          CACTGAGCCCAGCCTGTGGCTACTCAGGTGGCTTGAGCTGAATCTGGAGAAGGTGCTACC 
181         T  E  P  S  L  W  L  L  R  W  L  E  L  N  L  E  K  V  L  P  
 
          TCAGCCCCCTACGCCTTCCCAGGCCTGGAAAGTTGAACCTGAGGGTGCTGTCTTGGAACC  
201         Q  P  P  T  P  S  Q  A  W  K  V  E  P  E  G  A  V  L  E  P  
  
          AGATCCTCCAGGAACCCCTATGGAAGTGGAGCCCACAGAGAACCCCTCCCAGCCTAATCC 
221         D  P  P  G  T  P  M  E  V  E  P  T  E  N  P  S  Q  P  N  P  
 
          TGGACCCGTGGAGCCTGAGGAGGAGCCAGCCGCAGAGCCCCAGCCTGGCTTTCAAGCCTC 
241         G  P  V  E  P  E  E  E  P  A  A  E  P  Q  P  G  F  Q  A  S  
 
          TTCCCTGCCACCACCTGGGGACCCTGTCAGGCTGATCGAGTGGCTCCTACACAGGCTGGA 
261         S  L  P  P  P  G  D  P  V  R  L  I  E  W  L  L  H  R  L  E  
 
          GATGGCCCTGCCTCAGCCTGTGCTCCATGGGAAGGCTGCAGAGCAGGAGCCCAGCTGCCC 
281         M  A  L  P  Q  P  V  L  H  G  K  A  A  E  Q  E  P  S  C  P  
 
          TGGGACGTGTGACGTACAGACCATCAGCATCCTCCCTGTGGAACAGGCGGAACATGATCT 
301         G  T  C  D  V  Q  T  I  S  I  L  P  V  E  Q  A  E  H  D  L  
 
          TGTCCTCGAGGATGTGGACTCTTGCTGGGAGGACACCCAGCAGGAAGATGGTGCCAGCCT 
321         V  L  E  D  V  D  S  C  W  E  D  T  Q  Q  E  D  G  A  S  L  
 
          GCAGGAGACAGAGTTGGCTCCCATTTATGAAGACGAGAGTGAGGCCATGGTGGAGATGCC 
341         Q  E  T  E  L  A  P  I  Y  E  D  E  S  E  A  M  V  E  M  P  
inhibitory  
domain 1 
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          CAGGGAGCTGCCACAGATTCAAGAGCAGCAGGAAGAGGAGAATGAAGAGAAAGAAGAAGA 
361         R  E  L  P  Q  I  Q  E  Q  Q  E  E  E  N  E  E  K  E  E  E  
           
          GGAAGAAGAGAAGGAAGAGAAGGAAGAGAAGGAAGAGGAGGAAGAGAAGGAAGAGGAGGA 
381         E  E  E  K  E  E  K  E  E  K  E  E  E  E  E  K  E  E  E  E  
 
          GAAGAGGGAGGAAGAGAAGAAGAAAGAGAAGGAAGAGGAGAAGAAAGAGAAGGAAGAAGA 
401         K  R  E  E  E  K  K  K  E  K  E  E  E  K  K  E  K  E  E  E  
 
          GGAGAACGGGGAGGAAGAAGAGAAGGAAGAGAAGGAAGAAAAGGAAGAGGAGGAGGGGAA 
421         E  N  G  E  E  E  E  K  E  E  K  E  E  K  E  E  E  E  G  K  
 
          GGAAGAGAAGGAAGAGAAGGAAGAGAAGGAAGAAAAAGAAGAGGAGGAGAAGGAAGAAAA 
441         E  E  K  E  E  K  E  E  K  E  E  K  E  E  E  E  K  E  E  K  
 
          AGAAGAGGAGGAGAAGGAAGAAAAAGAAGAGGAGGAAGAGGAAGAGGAGGAAGAGGAGGA 
461         E  E  E  E  K  E  E  K  E  E  E  E  E  E  E  E  E  E  E  E  
 
          AGAGGAGCCTATTGTCCTGCTGGATAGCTGTTTGGTGGTGCAGGCTGATGTGGACCAGTG 
481         E  E  P  I  V  L  L  D  S  C  L  V  V  Q  A  D  V  D  Q  C  
 
          CCAGCTAGAAAGGGCACAGCCAGAGACAGCATCGATCCAGGAGTTACCAGAAGAAGAAGA 
501         Q  L  E  R  A  Q  P  E  T  A  S  I  Q  E  L  P  E  E  E  E  
 
          GGAGAAGGAGGAAGAGAAGAAGGAGGAGGAAGAGGAGAAGGAGGAGGAGGAAGAGAAGGA 
521         E  K  E  E  E  K  K  E  E  E  E  E  K  E  E  E  E  E  K  E  
 
          AGAGGAAGAGGAGAAGGAGGAGGAGGGGGAGGCCACAAACTCAACAGTACCAGCCACGAA 
541         E  E  E  E  K  E  E  E  G  E  A  T  N  S  T  V  P  A  T  K  
 
          AGAGCACCCGGAGCTCCAGGTGGAAGACACAGATGCCGAAGCTGGCCCCCTCATCCCAGA 
561         E  H  P  E  L  Q  V  E  D  T  D  A  E  A  G  P  L  I  P  E  
 
          GGAGACGATCCCGCCACCTGAGAGACCACCAGTGTCTCCCGCCAAGTCTGACACCCTCGC 
581         E  T  I  P  P  P  E  R  P  P  V  S  P  A  K  S  D  T  L  A  
 
          GGTTCCCAGCGCAGCAACCCACAGGAAGAAGCTACCTTCTCAGGATGATGAGGCTGAAGA 
601         V  P  S  A  A  T  H  R  K  K  L  P  S  Q  D  D  E  A  E  E  
 
          ACTCAAGGCCCTGTCACCGGCTGAGTCCCCAGTGGTTGCCTGGTCAGACCCCACCACCCC 
621         L  K  A  L  S  P  A  E  S  P  V  V  A  W  S  D  P  T  T  P  
 
          ACAGGAGGCTGATGGCGAGGACCGTGCGGCCTCCACAGCCAGCCAGAACAGTGCCATCAT 
641         Q  E  A  D  G  E  D  R  A  A  S  T  A  S  Q  N  S  A  I  I  
 
          CAACGACCGGCTCCAGGAGCTGGTGAAGATGTTCAAGGAGCGGACAGAGAAGGTGAAGGA 
661         N  D  R  L  Q  E  L  V  K  M  F  K  E  R  T  E  K  V  K  E  
 
          GAAGCTCATTGACCCTGACGTCACCTCCGATGAGGAGAGCCCCAAGCCCTCCCCAGCCAA 
681         K  L  I  D  P  D  V  T  S  D  E  E  S  P  K  P  S  P  A  K  
 
          GAAGGCCCCAGACTCAGCCCCAGCCCAGAAGCCGGCGGAGGCAGAGGCGGCAGAGGAGGA 
701         K  A  P  D  S  A  P  A  Q  K  P  A  E  A  E  A  A  E  E  E  
 
          GCACTACTGTGACATGCTCTGCTGCAAATTTAAGCGCAGGCCCTGGAAGATGTACCAGTT 
721         H  Y  C  D  M  L  C  C  K  F  K  R  R  P  W  K  M  Y  Q  F  
           
          CCCCCAGAGCATCGACCCACTGACCAACCTCATGTACATCCTGTGGCTGTTCTTCGTGGT 
741         P  Q  S  I  D  P  L  T  N  L  M  Y  I  L  W  L  F  F  V  V  
           
          GCTGGCCTGGAACTGGAACTGCTGGCTGATTCCTGTGCGCTGGGCCTTCCCGTACCAGCG 
761         L  A  W  N  W  N  C  W  L  I  P  V  R  W  A  F  P  Y  Q  R  
inhibitory  
domain 2 
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S3 S4 
S4 
S5 
S5 
S6 
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          GGCAGACAACATCCACCTCTGGCTGCTCATGGACTACTTGTGCGACTTCATCTACCTCCT 
781         A  D  N  I  H  L  W  L  L  M  D  Y  L  C  D  F  I  Y  L  L  
 
          GGACATCACCGTGTTCCAGATGCGTCTCCAGTTTGTCAAAGGCGGGGACATCATTACAGA 
801         D  I  T  V  F  Q  M  R  L  Q  F  V  K  G  G  D  I  I  T  D  
 
          TAAGAAGGAGATGCGTAATAATTACCTGAAGTCTCAACGATTTAAGATGGACTTGCTCTG 
821         K  K  E  M  R  N  N  Y  L  K  S  Q  R  F  K  M  D  L  L  C  
  
          CCTTTTGCCTTTGGATTTTCTCTACTTGAAACTTGGCGTGAACCCCCTTCTTCGCCTGCC 
841         L  L  P  L  D  F  L  Y  L  K  L  G  V  N  P  L  L  R  L  P  
 
          CCGCTGCCTGAAGTACATGGCCTTCTTTGAGTTTAATAACCGTCTGGAAGCCATCCTCAG 
861         R  C  L  K  Y  M  A  F  F  E  F  N  N  R  L  E  A  I  L  S  
  
          CAAAGCCTACGTTTACAGGGTTATCAGGACCACCGCCTACCTGCTGTATAGCTTGCATCT 
881         K  A  Y  V  Y  R  V  I  R  T  T  A  Y  L  L  Y  S  L  H  L  
  
          CAACTCCTGTCTTTACTACTGGGCGTCGGCCTTCCAGGGCATCGGTTCCACTCACTGGGT 
901         N  S  C  L  Y  Y  W  A  S  A  F  Q  G  I  G  S  T  H  W  V  
 
          TTATGACGGCGTGGGGAACAGCTACATTCGATGCTACTACTGGGCTGTGAAAACTCTCAT 
921         Y  D  G  V  G  N  S  Y  I  R  C  Y  Y  W  A  V  K  T  L  I  
  
          CACCATCGGAGGACTGCCCGACCCCCAGACGCTCTTTGAGATCGTCTTCCAGCTGCTGAA 
941         T  I  G  G  L  P  D  P  Q  T  L  F  E  I  V  F  Q  L  L  N  
 
          TTATTTTACAGGTGTCTTCGCTTTCTCTGTGATGATTGGACAGATGAGAGATGTGGTGGG 
961         Y  F  T  G  V  F  A  F  S  V  M  I  G  Q  M  R  D  V  V  G  
 
          GGCCGCCACGGCAGGGCAGACGTACTACCGCAGCTGCATGGACAGCACGGTGAAGTACAT 
981         A  A  T  A  G  Q  T  Y  Y  R  S  C  M  D  S  T  V  K  Y  M  
 
          GAACTTCTACAAGATCCCCAGGTCTGTGCAGAACCGCGTCAAGACCTGGTACGAATACAC 
1001        N  F  Y  K  I  P  R  S  V  Q  N  R  V  K  T  W  Y  E  Y  T  
 
          CTGGCACTCACAAGGCATGCTGGATGAGTCAGAGCTGATGGTTCAGCTTCCGGACAAGAT 
1021        W  H  S  Q  G  M  L  D  E  S  E  L  M  V  Q  L  P  D  K  M  
 
          GCGTCTGGACCTGGCCATTGACGTAAACTACAACATTGTCAGCAAAGTGGCGCTCTTCCA 
1041        R  L  D  L  A  I  D  V  N  Y  N  I  V  S  K  V  A  L  F  Q  
 
          GGGCTGCGACCGGCAGATGATCTTCGACATGCTCAAGCGACTTCGCTCAGTCGTCTACCT 
1061        G  C  D  R  Q  M  I  F  D  M  L  K  R  L  R  S  V  V  Y  L  
 
          ACCCAATGACTATGTGTGCAAGAAGGGGGAGATTGGCCGAGAGATGTATATTATCCAGGC 
1081        P  N  D  Y  V  C  K  K  G  E  I  G  R  E  M  Y  I  I  Q  A  
 
          GGGGCAGGTGCAGGTGCTGGGCGGCCCAGATGGAAAGGCTGTCCTGGTGACACTCAAAGC 
1101        G  Q  V  Q  V  L  G  G  P  D  G  K  A  V  L  V  T  L  K  A  
          
          CGGATCGGTGTTTGGAGAGATAAGCTTGCTGGCTGTCGGGGGCGGTAACAGGCGCACGGC 
1121        G  S  V  F  G  E  I  S  L  L  A  V  G  G  G  N  R  R  T  A  
           
          CAATGTGGTGGCCCACGGCTTCACCAATCTCTTCATTCTGGATAAGAAGGACTTGAATGA 
1141        N  V  V  A  H  G  F  T  N  L  F  I  L  D  K  K  D  L  N  E  
 
          GATTTTGGTGCATTACCCTGAATCTCAGAAGCTGCTCCGGAAGAAGGCCAGGCGCATGCT 
1161        I  L  V  H  Y  P  E  S  Q  K  L  L  R  K  K  A  R  R  M  L  
 
          CAGAAACAACAACAAACCCAAGGAGGAGAAGAGTGTGCTCATCCTGCCCCCACGTGCGGG 
1181        R  N  N  N  K  P  K  E  E  K  S  V  L  I  L  P  P  R  A  G  
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          CACCCCGAAGCTCTTCAATGCTGCCCTGGCTGCAGCAGGAAAGATGGGCCCCAGGGGAGC 
1201        T  P  K  L  F  N  A  A  L  A  A  A  G  K  M  G  P  R  G  A  
 
          CAAGGGCGGCAAGCTCGCCCACCTGAGAGCCAGGCTCAAAGAACTGGCTGCACTGGAGGC 
1221        K  G  G  K  L  A  H  L  R  A  R  L  K  E  L  A  A  L  E  A  
 
          AGCCGCACGACAGCAGCAGCTGCTGGAACAGGCCAAGAGCTCGCAAGAAGCCGGGGGAGA 
1241        A  A  R  Q  Q  Q  L  L  E  Q  A  K  S  S  Q  E  A  G  G  E  
 
          GGAGGGCTCTGGAGCCACAGACCAACCTGCACCCCAGGAGCCGTCAGAGCCCAAGGAGCC 
1261        E  G  S  G  A  T  D  Q  P  A  P  Q  E  P  S  E  P  K  E  P  
 
          CCCGGAGCCCCCAGCCCCGAGTTCTCCACCGCCAGCCTCAGCAAAGCCCGAGGGAAGCAC 
1281        P  E  P  P  A  P  S  S  P  P  P  A  S  A  K  P  E  G  S  T  
 
          GGAGGAGGCCGCAGGGCCGCCGGAGCCTTCAGTGAGGATCCGTGTGAGTCCAGGCCCTGA 
1301        E  E  A  A  G  P  P  E  P  S  V  R  I  R  V  S  P  G  P  D  
 
          TCCCGGGGAACAGACACTATCGGTGGAGATGCTGGAAGAGAAGAAGGAGGAGGTGGAG 
1321        P  G  E  Q  T  L  S  V  E  M  L  E  E  K  K  E  E  V  E 
 
 
Suppl. Fig.  1  Structural features of the rat CNGB1a. Shown are the two regions within the GARP 
domain which confer the most part of the inhibitory effect as measured by L-cis-diltiazem sensitivity 
(cf. Fig. 17). For better orientation, six transmembrane domains (S1-S6) and cyclic nucleotide binding 
domain (CNBD, blue font) are also highlighted within the sequence. Numbers on the left refer to the 
amino acid positions at the beginning of each line.  
 
 
Suppl. Table 1 List of primer used for the synthesis of different mutagenesis constructs. 1+2: 
mutagenesis for CNGB1aGV, 3+4 B1a#556-1339, 5+6 ∆214-555, 5+7 B1a#1-555, 8+10 ∆1-481, 9+10 
∆1-363.  
 Name  Gene Sequence 5‘-3‘ 
1 B1_MutG-V_F Rat CNGB1 ATGTGTGCAAGAAGGTGGAGATTGGCCGAG 
2 B1_MutG-V_R Rat CNGB1 CTCGGCCAATCTCCACCTTCTTGCACACAT 
3 Oligo HindXho1 Rat CNGB1 AGCTTGAATTCGCCACCATGGTAC 
4 Oligo HindXho2 Rat CNGB1 CATGGTGGCGAATTCA 
5 B1aKpnfor Rat CNGB1 CTATAGGGAGACCCAAGCTTGG 
6 KpnAAErev Rat CNGB1 CCGGTACCTCTGCGGCTGGCTCCTCC 
7 B1aTNSTXbarev Rat CNGB1 CCTCTAGAGCTGTTGAGTTTGTGGCCT 
8 KpnKzkEPIV_F Rat CNGB1 CCGGTACCGCCACCATGGAGCCTATTGTCCTGCTGG 
9 KpnKzkPQIQfor Rat CNGB1 CCGGTACCGCCACCATGCCACAGATTCAAGAGCAGC 
10 B1BsrGIrev Rat CNGB1 CGAAGAACAGCCACAGGATG 
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Suppl. Table 2 List of primer used for amplification of different human CNG channel 
constructs. 
 Name  Gene Sequence 5‘-3‘ 
1 hB1aKzkBamfor Human 
CNGB1 
CCGGATCCACCGCCATGTTGGGCTGGGTCCAGAG 
2 hB1Xhorev Human 
CNGB1 
GGCTCGAGTCCGCCTTCTCCTCCCTTTC 
3 KpnKzkhB1adNTfor Human 
CNGB1 
CCGGTACCGCCACCATGGTGCCTGCCACGAAACAGC 
4 hA1KzkEcofor Human 
CNGA1 
CCGAATTCACCGCCATGAAACTATCCATGAAGAAC 
5 hA1Salrev Human 
CNGA1 
CCGTCGACTATGTAGAGTCGATGGGCC 
6 hB1G993Vfor Human 
CNGB1 
ACTATGTGTGCAAGAAGGTGGAGATCGGCCGTGAGAT 
7 hB1G993Vrev Human 
CNGB1 
ATCTCACGGCCGATCTCCACCTTCTTGCACACATAGT 
8 KzkhdNT9for Human 
CNGB1 
GCCACCATGTCCCGGATTGAAGAGGAGAAAG 
9 KzkhdNT8for Human 
CNGB1 
GCCACCATGGTGACTGAGGTGCTGCTGG 
 
 
 
Suppl. Table 3 List of primer used for the synthesis of FRET constructs. 1+2, YFP-CNGB1a. 3+4 
CNGA1-CFP.  
 Name  Gene Sequence 5‘-3‘ 
1 YFPKpnfor Rat CNGB1 GTCGGTACCATGGTGAGCAAGGGCG 
2 YFPB1rev Rat CNGB1 GACCCAGCCCAACATCTTGTACAGCTCGTCCATGCC 
3 InfmA1CFPfor Bovine CNGA1 GGGGAAAGTGGGCCCACAGACTCTACACAGGAC 
4 InfmA1CFPrev Bovine CNGA1 CTATAGAATAGGGCCCTCTAGATGCATGC 
 
 
 
Suppl. Table 4 Primer used for PCR amplification of minigene constructs and splice products 
(1-4). Numbers 5-6 represent the primer used for site directed mutagenesis (introduction of the 
c.3444+1G>A mutation). 
 Name  Gene/Vector Sequence 5‘-3‘ 
1 hB1a_in30F Human CNGB1 CGAAACGGCAGTCTCTGAAGG 
2 hB1a_e33R Human CNGB1 CACACCTGCTGGAACTGC 
3 pcDNA3_F pcDNA3 CTAGAGAACCCACTGCTT  
4 pcDNA3_R pcDNA3 GCACAGTCGAGGCTGATC  
5 hB1aKondoF Human CNGB1 GAGTTGGTGGAACAGATAATGTGGTTGGGAAC 
6 hB1aKondoR Human CNGB1 GTTCCCAACCACATTATCTGTTCCACCAACTC 
 58 Appendix 
 
 
 
Suppl. Table 5 Antibodies used in this study. 
 
Antibody Source Dilution Secondary 
antibody 
Dilution 
anti-ATPase 
clone α6F 
Developed by D.M. Fambrough, obtained 
from the Developmental Studies Hybridoma 
Bank 
1:1000 anti-mouse 1:2000 
anti-CNGB1 Hüttl 2005 J Neurosci 1:10000 anti-rabbit 1:2000 
anti-GFP Clontech, Mountain View 1:1000 anti-mouse 1:2000 
anti-myc clone 
9B11 
New England Biolabs 1:1000 anti-mouse 1:2000 
PPc6N Colville CA, Molday RS [23] 1:1000 anti-rabbit 1:2000 
anti-tubulin Dianova, Hamburg, Germany 1:400 anti-mouse 1:2000 
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7.2 Abbreviations 
 
aa  amino acids 
BES  N-N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid 
bp   base pairs  
BSA   bovine serum albumin 
cAMP  cyclic adenosine monophosphate 
CAP  catabolite gene activator protein 
cDNA   complementary DNA 
CFP  cyan fluorescent protein 
cGMP  cyclic guanosine monophosphate 
CMV  cytomegalovirus 
CNBD  cyclic nucleotide-binding domain 
CNG   cyclic nucleotide-gated 
ddH2O  double deionized water  
DEPC   diethyl pyrocarbonate 
DMEM  Dulbecco's modified eagle medium 
DMSO  dimethylsulfoxide 
DNA   deoxyribonucleic acid 
dNTP  2’-desoxynucleoside-5’-triphoshate (dATP, dCTP, dGTP, dUTP or dTTP) 
DTT   dithiothreitol 
E. coli   Escherichia coli 
EDTA   ethylenediaminetetraacetic acid 
GFP  green fluorescent protein 
FBS  fetal bovine serum 
h   hour 
HCl   hydrochloric acid 
HCN  hyperpolarisation activated cyclic nucleotide-gated channel 
HEK293  human embryonic kidney cells 
HRP   horseradish peroxidase 
IgG  immunoglobulin G 
kb   kilobase pairs  
kDa   kilodalton 
KO   knockout 
LB broth  Luria-Bertani broth 
mA   milliampere 
MD  molecular dynamics 
MCS  multiple cloning site 
mg   milligram 
min   minute 
mL   milliliter  
MOPS  3-[N-Morpholino]propanesulfonic acid 
mRNA  messenger RNA 
µg   microgram 
NMD  nonsense mediated mRNA decay 
NP-40  nonyl phenoxylpolyethoxylethanol 
Ori  origin of replication 
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PBS   phosphate buffered saline 
PCR   polymerase chain reaction 
PFA   Paraformaldehyde 
PKA  cAMP dependent protein kinase 
Pmax  maximal channel open probability 
pmol   picomol 
PVP   polyvinylpyrrolidone 
RNA   ribonucleic acid 
RNase  ribonulease 
RP   retinitis pigmentosa 
Rpm  rotations per minute 
RT-PCR  reverse transcriptase PCR 
SDS   sodium dodecylsulfate 
sec   second 
TEMED  N,N,N',N'-TetramethyIethylendiamine 
TRIS   tris(hydroxymethy1)aminomethane 
UV  ultraviolet 
WT   wild type 
YFP  yellow fluorescent protein 
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